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During cancer progression, the extracellular matrix (ECM) is extensively remodeled. The 
ECM molecule tenascin-C is an adhesion-modulating molecule, which is highly expressed in 
tumor stroma. Tenascin-C was shown to disrupt the interaction of cells with fibronectin, an 
adhesive ECM molecule, through inhibition of  syndecan-4, the co-receptor of the fibronectin 
binding integrin α5β1. Cells on a mixed substratum of fibronectin and tenascin-C failed to 
form cell adhesion structures and actin stress fibers and thus remained rounded. Focal 
adhesion kinase (FAK) (Huang et al., 2001; Orend, 2003) and the small GTPase RhoA 
(Wenk et al., 2000), two molecules with an important role in formation of focal adhesions and 
actin stress fibers, were downregulated in the presence of tenascin-C. Furthermore, the 
actin-binding and filament-stabilizing molecule tropomyosin-1 (TM1) was identified by Ruiz et 
al., (2004) to be downregulated by tenascin-C and its downregulation contributed to the lack 
of actin stress fiber formation on a fibronectin/tenascin-C substratum.  
 
Here, we investigated the signaling events, that lead to cell rounding by tenascin-C. In 
particular, we wanted to understand how tenascin-C prevents the formation of focal 
adhesions and stress fibers, and how tenascin-C affects expression and function of the three 
downstream targets FAK, RhoA and TM1. First, we investigated whether inhibition of 
syndecan-4 by tenascin-C is linked to reduced expression of RhoA and TM1 and inhibition of 
FAK. By activating syndecan-4 on fibronectin/tenascin-C substratum we observed that 
indeed this is the case. Thus, repression of FAK, RhoA and TM1 could explain the lack of 
actin stress fiber formation on fibronectin/tenascin-C.  
 
Whereas expression of TM1 was not regulated by tenascin-C at the transcriptional level, it 
turned out that tenascin-C repressed RNA levels of two other tropomyosins TM2 and TM3, 
which are far less expressed in T98G cells than TM1. Apparently, lowered levels of TM2 and 
TM3 affected TM1 protein heterodimer stabilization through proteasomal degradation that 
was largely enhanced on fibronectin/tenascin-C. This possibility was supported by our 
observation that inhibition of the proteasome restored TM1 expression on this mixed 
substratum. Our data suggest that tenascin-C does not only repress gene expression of 
tropomyosins but also enhances their proteasome-mediated protein degradation. Repression 
of TM1, a molecule with a tumor suppressor-like activity, by tenascin-C might be relevant in 
cancer, since low levels of this molecule can protect cancer cells from apoptosis. 
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To learn more about the underlying mechanism of tenascin-C-induced cell rounding, we 
searched for signaling pathways, that enabled cells to spread in the presence of tenascin-C. 
In addition, we used knockdown and overexpression studies together with chemical 
inhibitors. Our data suggest that concomittant restoration of the expression and function of all 
three downstream targets FAK, RhoA and TM1, is necessary to induce cell spreading on a 
fibronectin/tenascin-C substratum. In particular, we observed that activation of endothelin 
receptor type B (EDNRB) induced spreading in the presence of tenascin-C. This was 
dependent on PI3K, PLC and JNK, since chemical inhibitors of these enzymes blocked 
EDNRB-induced cell spreading on fibronectin/tenascin-C. Signaling by EDNRB was linked to 
activation of FAK and paxillin and restoration of TM1 and RhoA expression, again supporting 
our notion that inactivation of these molecules is critical for tenascin-C-induced cell rounding.  
 
Based on the results from Ruiz et al., (2004), that described an enhanced expression of 
endothelin receptor type A (EDNRA) in the presence of tenascin-C, we wanted to know 
whether and how EDNRA signaling contributes to cell rounding by tenascin-C. EDNRA 
expression was triggered by tenascin-C upon contact with the substratum for more than 5 h. 
We demonstrated that EDNRA signaling is linked to cell rounding on a fibronectin/tenascin-C 
substratum through inhibition of FAK and repression of RhoA and TM1. Collectively, these 
data suggest that inhibition of syndecan-4 is responsible for initial cell rounding and that upon 
induction of EDNRA by tenascin-C, EDNRA maintains cell rounding on a 
fibronectin/tenascin-C substratum at later time points. In gliomas and other cancers we found 
a high expression of tenascin-C and EDNRA, that correlated with more advanced stages, 
which supports the possibility that tenascin-C potentially promotes tumor progression through 
EDNRA.  
 
In addition to EDNRB, concomittant activation of the receptors for lysophosphatidic acid 
(LPA) and platelet-derived growth factor (PDGF) also enabled cells to spread on a 
fibronectin/tenascin-C substratum by a mechanism, which again involved restoration of the 
expression and function of FAK, paxillin, RhoA and TM1. By using cells lacking syndecan-4, 
we observed that LPA/PDGF bypassed the requirement for syndecan-4 in cell spreading on 
a mixed substratum. Knockdown of paxillin prevented LPA/PDGF-induced cell spreading on 
fibronectin/tenascin-C, which suggests an essential role of paxillin in LPA/PDGF induced cell 
spreading in presence of tenascin-C. In further support of an important role of paxillin in 
LPA/PDGF-induced cell spreading, we showed that ectopic expression of syndesmos, a 
molecule that binds syndecan-4 and paxillin, enabled cells to spread on fibronectin/tenascin-
C. We showed that expression levels of TM1 are critical for cell rounding and cell spreading 
in the presence of tenascin-C, respectively. Whereas ectopic expression of TM1 restored cell 
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spreading on fibronectin/tenascin-C, knockdown of TM2/3 prevented LPA/PDGF-induced cell 
spreading on the mixed substratum. We also observed, that TM1 levels were tightly linked to 
expression of RhoA and activation of FAK, which suggests an interdependent regulation. 
 
We observed that activation of the receptors for endothelin-1 (ET1) (EDNRB), and 
LPA/PDGF induced spreading in the presence of tenascin-C by distinct pathways. Whereas 
EDNRB-induced spreading was dependent on PI3K, PLC and JNK, but not on MEK, 
LPA/PDGF-induced cell spreading was dependent on PI3K and MEK, but not on PLC and 
JNK. Signaling by these factors was linked to activation of FAK and paxillin and, restoration 
of TM1 and RhoA expression. Together, our results suggest that at least two (and 
presumably many more) mechanisms exist that modulate the adhesive strength of a 
fibronectin/tenascin-C substratum. This supports the notion that combined signaling from the 
ECM and growth factors can determine cell adhesion and migration. 
 
ET1 (through EDNRB) and LPA/PDGF did not only trigger cell spreading in the presence of 
tenascin-C but also stimulated cell migration on this substratum. In particular, LPA/PDGF-
induced cell migration was PI3K and ROCK dependent. By using cells with ectopic 
expression of syndesmos and TM1, or reduced expression of TM1-3, we showed that both a 
strong as well as a loose adhesion blocked LPA/PDGF-induced cell migration on 
fibronectin/tenascin-C. These observations might be important for cancer diagnosis and may 
eventually allow to develop novel cancer treatments. In particular, we find that in gliomas a 
high expression of tenascin-C and of PDGF receptors a and b correlates with malignancy. 
Moreover, a high expression of syndesmos correlates with a bad 5 year survival prognosis 
and chemotherapy response rate in patients with oligodendrogliomas. 
 
In summary, here it was shown that cell adhesion and migration on an anti-adhesive 
fibronectin/tenascin-C substratum can be modulated by additional signaling from growth 
factors. We identified a minimal set of critical targets of tenascin-C downstream of syndecan-
4 that include FAK, paxillin, RhoA and TM1. Induction of EDNRA signaling by tenascin-C 
provides an additional mechanism that contributes to maintained cell rounding by a 
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1.2 Extracellular matrix 
 
The extracellular matrix (ECM) is a complex structural entity surrounding and supporting cells 
that are found within mammalian tissues. This matrix is composed of a variety of proteins 
and polysaccharides that are secreted locally and assembled into an organized meshwork in 
close association with the surface of the cell that produced them. The ECM has an active 
and complex role in regulating the behaviour of the cells that contact it. It determines their 
survival, development, migration, proliferation, cell shape and function. There are four 
prototypes of macromolecules of the ECM: collagens, elastin, proteoglycans and 
glycoproteins. One main family of the matrix glycoproteins are the nectins, such as 
fibronectin, vitronectin, thrombospondin and tenascin, which transducer signals to the cells 
embedded in the ECM. During cancer progression, the ECM of the tissue in which the tumor 
grows, is extensively remodelled, both by degradation of pre-existing ECM molecules and by 
neosynthesis of ECM components, which in many cases are not present in the ECM of 
normal tissue (Kaspar et al., 2006).  
 
1.2.1 Fibronectin   
  
Fibronectin (FN), a highly conserved multidomain adhesive glycoprotein, plays a prominent 
role in mediating ECM function. Secreted fibronectin usually forms dimers composed of two 
similar but not necessarily identical subunits of 250-280 kDa joined by a pair of disulfide 
bonds near their carboxyl terminal end (Ruoslathi, 1988). Each subunit contains three 
different types of repeating modular domains: 12 type I, 2 type II and 15 to 17 type III 
domains (Fig. 1), separated by regions of a flexible polypeptide chain. These domains are 
resistant to proteolysis, and may contain binding sites for ECM proteins such as collagen, 
cell-surface receptors (integrins), blood protein dervivatives (fibrin) and glycosaminoglycans 
(heparin). fibronectins play a critical role in the maintenance of normal cell morphology, cell 
adhesion, migration, hemostasis, thrombosis, wound healing, differentiation and proliferation 
(Hynes, 1990). A single gene encodes fibronectin but alternative splicing of pre-mRNA as 
well as posttranslational modifications allow formation of multiple isoforms, with up to 20 
variants possible in human tissues (Schwarzbauer, 1991). Especially the fibronectin type III 
(FNIII) repeats are particulary widespread and one protein family that contains fibronectin 
type III repeats, is the tenascin family. The cell-binding domain contains a specific consensus 
tripeptide sequence, RGD sequence (Arg-Gly-Asp), which is recognised by several members  
of the integrin family of cell-surface matrix receptors, such as α5β1 and αvβ3 (Pankov and 
Yamada, 2002; Clark and Brugge, 1995). The RGD sequence is located within the FNIII10 
repeat. In addition, the adhesive region in FNIII9 has been called the synergy site (Obara et 
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al., 1988; Kimizuka et al., 1991) and is necessary for Integrin binding to FNIII10. Mutant 
mice, unable to produce fibronectin die early in embryogenesis because their endothelial 
cells fail to form proper blood vessels, which demonstrates an essential role of fibronecton in 
embryonic development.  




are needed to see this picture.
 
            





















 Fig.1: Overviev over domain composition of fibronectin and molecules binding to distinct 
domains.  
In this scheme of fibronectin, narrow boxes, ovals, and wide boxes represent fibronectin type I, II, and III 
repeats, respectively. The heparin-binding sites (HepI-III), RGD, and the synergy site are marked and 
aligned with ineracting cell surface receptors (integrins; e.g., α5β1), syndecan-4 (S4), and chondroitin of 
the recombinant fragments used and binding to tenascin-C are depicted above the model. 
Huang et al., 2001  .2 Tenascin-C 
nascins are a family of large multimeric ECM proteins. Vertebrates express four tenascins 
med tenascin-C, -R, -X and –W present in their connective tissues, with each tenascin 
ving a specific expression pattern (Chiquet-Ehrismann, 2004). Tenascin-C (TNC) is an 
hesion modulatory ECM molecule that is highly expressed in the microenvironment of 
st solid tumors, and indicates potential roles in tumor growth, metastasis, angiogenesis 
d immuno suppression (Orend and Chiquet-Ehrismann, 2003). Tenascin-C is highly 
pressed during embryogenesis, but in the adult organism its expression is restricted to a 
 sites under non-pathological conditions. Tenascin-C was also detected in stem cell 
hes (reviewed in Orend, 2005), as well as in T-lymphocyte-dependent zones in bone 
rrow, spleen, thymus and lymph nodes (Castanos-Velez et al., 1995). It is also induced in 
thological conditions such as inflammation and wound healing (reviewed in Jones and 
nes, 2000).  
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Tenascin-C is a huge molecule of about 300 kDa as an intact monomer and up to 1800 kDa 
when assembled into a hexamer. The multidomain molecule consists of an N-terminal 
assembly domain, followed by heptad- and 14 ½ EGF-like repeats, eight constant and up to 
9 alternatively spliced fribronectin type III repeats and a C-terminal fibrinogen-like globular 
domain (see Fig. 2.2). Some studies have found certain alternatively spliced fibronectin type 
III repeats to be expressed in different cancer types (Fig. 2). Tenascin-C splice variants with 
extra repeats B/D are found in ductal carcinoma in situ (Adams et al., 2002) and with extra 
repeats A1/A2/A4 in invasive colorectal carcinoma (Dueck et al., 1999). The extra repeats 
AD1 were spliced in malignant human melanoma and ductal breast carcinoma (Derr et al., 
1997), the extra repeat AD2 in malignant oral cancers (MIghell et al., 1997) and repeat C in 















Fig. 2: Schematic representation of tenascin-C binding molecules (taken from Orend, 
2005).  
The N-terminal region, EGF-like, fibronectin type III anf fibrinogen-like domains are 
schematically depicted as triangle, rhombomeres, boxes and circle, respectively. The 
alternatively spliced fibronectin type III repeats A1-D found in human tenascin-C are highlited. 
Binding sites for interacting molecules within tenascin-C are shown: (a) Proteintyrosine 
phosphatase-β/ξ (RPTPβ) (Milev et al., 1997); (b) weak binding to EGF receptor (EGFR) in a 
mM KD range (Swindle et al., 2001); (c) integrins αvβ3, αvβ6 (Yokosaki et al., 1996), and 
α8β1 (Denda et al., 1998) bind to RGD, α9β1 binds to IDG (Yokosaki et al., 1994); (d) 
fibronectin, fibronectin type III repeats 1-5 (Hauzenberger et al., 1999) and 6-8 (Chung et al., 
1995); (e) the lecticans aggrecan, versican and neurocan bind to TNfnIII3-5 and to TNfnIII6-8 
in a KD range of 30-40 nM and 40-70 nM, respectively. Brevican binding to both regions 
within fibronectin was weaker in a µM KD range (Day et al., 2004); (f) perlecan (Chung and 
Erickson, 1994); (g) contactin (Zisch et al., 1992); (h) neourocan (Rauch et al., 2001); (i) 
integrin α7β1 (Mercado et al., 2004); (j) sodium channel subunit β2 (Srinivasan et al., 1998); 
(k) annexin II (Chung and Erickson, 1994); (l) integrin αvβ3 (Yokoyama et al., 2000); (m) 
CALEB, chicken acidic leucine-rich EGF like domain containing brain protein (Schumacher et 
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Tenascin-C was shown to disturb the interaction of cells with fibronectin which leads to an 
increased proliferation of tumor cells (Chiquet-Ehrismann et al., 1988). The binding between 
tenascin-C and fibronectin does not involve the RGD-site of fibronectin. Recently it has been 
shown that tenascin-C binds to the fragments FNIII4-6 and FNIII13, but not to the fragment 
FNIII7-10 which includes the RGD site (Huang et al., 2001).  
Apart from variations in the modular structure caused by alternative splicing, cleavage by 
matrix metalloproteinases (MMPs) can lead to specific domains being present in certain 
tissues. Tenascin-C has been shown to be cleaved by MMP7 and MMP2 (Siri et al., 1995). In 
melanoma cells, tenascin-C variants have been found that resemble the products of an in 
vitro cleavage of tenascin-C by the MMPs 1, 3 and 7 (Imai et al., 1994). The presence of 
tenascin-C leads to the induction or activation of certain MMPs.  
Tenascin-C knock-out mice are viable, but show defects and deficits in the nervous system 
(reviewed in Chiquet-Ehrismann and Chiquet, 2003) and other tissues upon insults disrupting 
their homeostasis (Tucker and Mackie, 1999). Together with a very high conservation of its 
sequence throughout the kingdom of mammals, this demonstrates that tenascin-C is 
presumably essential foe life and its absence is compensated by several not well understood 
mechanisms.   
 
1.2.3 Integrins    
 
Cells interact with the ECM mainly via integrins, which display the major cell surface 
receptors for ECM ligands. They are widely expressed in all cell types in the body. Integrins 
comprise a heterodimer of two chains, termed α and β, which together form a ligand binding 
site and have short cytoplasmic domains that assemble a complex of kinases, adaptor 
proteins, and other signaling molecules following ligand binding, thus initiating downstream 
signaling pathways (Baron et al., 2004). The integrin family is comprised of 18 α and 8 β 
transmembrane subunits that form 24 different α/β-heterodimeric receptors for diverse ECM 
proteins (Hynes, 2002). Ligand binding to integrins initiates conformational changes in the 
integrin extracellular domain, integrin clustering and recruitment of cytoskeletal and signaling 
molecules (Dedhar and Hannigan, 1997; Shimoka et al., 2002). Besides structural functions, 
integrins transduce signals for the regulation of, for example, cell survival and proliferation in 
an outside-in and inside-out manner (Giancotti and Ruoslahti, 1999; Schwartz and Assoian, 
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The integrin α5β1 binds the ECM protein fibronectin and enables not only cell adhesion and 
cytoskeleton organization but also transduction of critical signals into the cells to promote 
survival, proliferation, differentiation, or migration programs. The primary binding site for this 
interaction is the RGD sequence in FNIII10, but within FNIII9 the PHSRN sequence provides 
synergistic effects for full α5β1 binding to fibronectin (Main et al., 1992; Aota et al., 1994).  
A successful vascular development depends on fibronectin and its major receptor α5β1 
integrin, but not on αvβ3, αvβ5, and α6β4 integrins that are instead central regulators of 
postnatal tumor angiogenesis (Serini et al., 2005). Tumor-associated blood vessels over-
express fibronectin and its receptor α5β1, whereas the quiescent vasculature does not 
express these molecules, which confirms the importance of α5β1 integrins in pathological 
angiogenesis (Kim et al., 2000; Taverna and Hynes, 2001; Mettouchi and Meneguzzi, 2006).   
 
1.2.4 Syndecan-4    
  
The cell-surface heparin sulphated proteoglycan syndecan-4 acts in conjunction with the 
α5β1 integrin to promote the formation of actin stress fibers and focal adhesions in 
fibronectin-adherent cells, which will be discussed later. Syndecans are type I membrane 
proteins, with an N-terminal signal peptide, an ectodomain with several glycosaminoglycan 
attachment sites, a single transmembrane domain and a short C-terminal cytoplasmic 
domain. Syndecan core proteins range in size from 20 to 45 kDa. The ectodomains of 
syndecans display low sequence homology, whereas their transmembrane and cytoplasmic 
domains are highly conserved (reviewed in Woods, 2001; Woods et al., 1998; Carey, 1997; 
Bernfield et al., 1999). The cytoplasmic domain of each syndecan has two highly conserved 
regions, C1 and C2, proximal and distal to the membrane. A variable (V) region unique to 
each syndecan is flanked by the C1 and C2 regions (Yoneda and Couchman, 2003). 
Although all members of the syndecans arose from a single ancestral gene, their expression 
patterns in tissues and during development are highly regulated (Woods et al., 1998; Carey, 
1997; Bernfield et al., 1999). The terminal four amino acids (EFYA) of the cytoplasmic 
domain of all syndecan family members compose a binding site for the PDZ-containing 
proteins: synbindin, syntenin, CASK/LIN-2 and synectin (Fig. 3) (Ethell et al., 2000; Hsueh 
and Sheng, 1999; Gao et al., 2000; Grootjans et al., 1997). Syndesmos is another adaptor 
protein that binds to the cytoplasmic tail of syndecan-4 (Denhez et al., 2002). Syndecan-4 is 
the only family member to localize to sites of cell-matrix adhesions (Woods et al., 2000). 
Comparison of the localization of syndecan-4 with the focal adhesion marker protein vinculin 
suggests that syndecan-4 does not localize to newly formed contacts but with more 
established adhesion sites (Woods and Couchman, 1994).  
 15
                                                                                                                                                              Introduction 
                                                                                                                                                                                              
 
 
              
 
Fig. 3: Syndecan-4 acts as an organizing centre for transmembrane receptors and is 
anchored to the actin cytoskeleton. 
The cytoplasmic domains of syndecan-4 interact with scaffold proteins, such as syntenin and 
CASK, that might in turn recruit additional transmembrane receptors (such as intergrins, 
phosphatases and growth factor receptors) to adhesions. Syndecan-4 is also linked to the actin 
cytoskeleton through CASK and the ERM family of actin-binding proteins. Clustering of 
syndecan-4 into focal adhesions is essential for adhesion formation in cells adhering via 
integrin α5β1, and may depend on both a mechanical link between receptors and activation of 
signaling pathways. PTP, protein tyrosine phosphatase; 1 and 2 represent PDZ domains 1 and 
2 respectively.  









Mice, heterozygous or homozygous for a disrupted syndecan-4 gene (by homologous 
recombination) exhibit a statistically significant delay in the healing of skin wounds and show 
impaired angiogenesis in granulation tissue (Echtermeyer et al., 2000).  
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 1.3 Formation of focal adhesions    
 
Cell adhesion is important for such biological functions as cell growth, proliferation, survival, 
and migration. Cells adherent to ECM proteins (i.e. fibronectin) in vitro, cluster membrane 
adhesion receptors and intracellular cytoplasmic adaptor and signaling molecules into 
macromolecular complexes termed focal adhesions (Burridge and Chrzanowska, 1996). 
Focal adhesions are highly specialized type of attachment between actin filaments and the 
extracellular matrix that allows cells to pull on the substratum to which they bound. They 
create spots where the normal 50 nm gap between the bottom of the cell and the substratum 
is reduced to only 10-15 nm. At these sites, stress fibers, consisting of contractile bundles of 
actin and myosin II filaments, terminate at the plasma membrane, where clusters of intergrins 
are located. Their intracellular domains bind directly to bundles of actin filaments via the 
intracellular anchor proteins such as talin, vinculin, filamin, α-actinin, paxillin and focal 
adhesion kinase (FAK), which are recruited into focal adhesions. Previous studies have 
demonstrated that fibroblasts seeded onto an RGD-containing cell-binding domain (CBD) of 
fibronectin will attach but will not spread nor form focal adhesions and actin stress fibers 
(Saoncella et al., 1999; Woods et al., 1986). Denez et al., 2002, showed that syndecan-4, 
working in cooperation with the α5β1 integrin, can stimulate a Rho-dependent pathway that 
will elicit focal adhesion and stress fiber formation in CBD-adherent cells. Thus, syndecan-4 
and Integrin ligation is necessary for full cell spreading on fibronectin. 
 
 1.3.1 Focal adhesion kinase (FAK) 
    
A large body of evidence has demonstrated that a rapid increase in the tyrosine 
phosphorylation of the non-receptor tyrosine kinase FAK is a prominent early event in 
fibroblasts stimulated by diverse signaling molecules that regulate cell proliferation, migration 
and survival, including mitogenic agonists that act via G protein-coupled receptors (GPCR), 
growth factors, integrin clustering by cell adhesion, and bacterial toxins (Zachary and 
Rozengurt, 1992; Rozengurt, 1995; Hanks and Polte, 1997; Schlaepfer et al., 1999; Schaller, 
2001; Parson, 2003). FAK is an ubiquitinously expressed 125 kDa protein, which is 
composed of an N-terminal FERM (protein 4.1, ezrin, radixin and moesin homology) domain, 
a central kinase domain, prolin-rich regions and a C-terminal focal-adhesion targeting (FAT) 
domain (see Fig.). The best-characterized FAK phosphorylation event is autophosphorylation 
at Tyr397, which can occur in either cis or trans (Toutant, 2002). Phosphorylation of FAK at 
Tyr397 creates a motif that is recognized by various SH2-domain-containing proteins, such 
as Src-family kinases (SFKs), phospholipase Cγ (PLCγ), suppressor of cytokine signalling 
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(SOCS), growth-factor-receptor-bound protein-7 (GRB7), the Shc adapter protein, 
p120RasGAP, and the p85 subunit of phosphatidylinositol 3-kinase (PI3K) (Fig. 4) (Parson, 
2003; Schlaepfer et al., 2004; Hanks et al., 2003; Schaller, 2001).     
   
























 Fig. 4: Focal adhesion kinase domain structure and phosphorylation sites.  
The FERM domain mediates interactions of FAK with the epidermal growth factor (EGF) receptor, 
platelet-derived growth factor (PDGF) receptor, the ETK tyrosine kinase and ezrin, and the FERM 
domain can be conjugated to SUMO (small ubiquitin-related modifier) at Lys152. The FAT domain 
recruits FAK to focal contacts by associating with integrin-associated proteins such as talin and 
paxillin. It also links FAK to the activation of Rho GTPases by binding to guanine nucleotide-exchange 
factors (GEFs) such as p190 RhoGEF. FAK contains three praline-rich regions (PRR1-3), which bind 
Src-homology-3 (SH3) domain-containing proteins such as p130Cas, the GTPase regulator 
associated with FAK (GRAF) and the Arf-GTPase-activating protein ASAP1. FAK is phosphorylated at 
(P) at several tyrosine residues, including Tyr397, 407, 576, 577, 861 and 925. Tyrosine 
phosphorylation on Tyr397 creates a Src-homology-2 (SH2) binding site for Src, phospholipase Cγ 
(PLCγ), suppressor of cytokine signalling (SOCS), growth-factor-receptor-bound protein 7 (GRB7), the 
Shc adaptor protein, p120 Ras GAP and the p85 subunit of phosphatidylinositol 3-kinase (PI3K). 
Phosphorylation of Tyr576 and Tyr577 within the kinase domain is required for maximal FAK catalytic 
activity, whereas the binding of FAK-family interacting protein of 200 kDa (FIP200) to the kinase 
region inhibits FAK catalytic activity. FAK phosphorylation at Tyr925 creates a binding site for GRB2. 
Reviewd in Mitra et al., 2005)   r910, a further important phosphorylation site within the FAT domain is phosphorylated 
ring mitosis (Ma et al., 2001) and after growth factor stimulation of cells. Ser910 is 
osphorylated by ERK2 and this is also associated with reduced paxillin binding to FAK 
unger-Glaser et al., 2004).  
K-mediated signal transduction is underscored by the fact that this tyrosine kinase plays a 
damental role in embryonic development (Ilic et al., 1995; Ilic et al., 1997)) and in the 
ntrol of cell migration, cell cycle progression (Zhao et al., 2003) and apoptosis (Hungerford 
al., 1996; Xu et al., 1996; Gervais et al., 1998; Golubovskaya et al., 2003). Furthermore, 
re is increasing evidence linking overexpression of FAK to the invasive properties of 
ncer cells (Owens et al., 1996; Mukai et al., 2002; Gabarra-Niecko et al., 2003; Hsia et al., 
03; Sood et al., 2004; Schlaepfer et al., 2004). However, focal contacts in in FAK-/- cells 
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form primarily around the cell periphery, enmeshed in a cortical actin ring, and do not 
undergo a normal maturation cycle (Sieg et al., 1999). Compensation by the FAK homologue 




Paxillin is a 68 kDa phosphoprotein originally identified as a substrate for the non-receptor 
tyrosine kinase Src in Rous sarcoma virus-transformed fibroblasts (Glenny and Zokas, 1989; 
Turner at al., 1990). This multi-domain adaptor protein has previously been implicated in 
integrin signaling, cell motility (Turner et al., 2005) and disassembly of focal adhesions 
(adhesion turnover) in the protrusion of migrating cells (Horwitz et al., 2006). Functionally, 
paxillin has been implicated in the regulation of cell adhesion, spreading, muscle 
differentiation and gene expression through its ability to directly interact with multiple 
structural and signaling proteins involved in coordinating these events, such as tubulin, 
p120RasGAP, PKL, PTP-PEST, FAK, Src, Crk and Csk (Turner et al., 2005) (Fig. 5). 
Structurally, paxillin consists of an N-terminal region containing five LD protein-protein 
interaction motifs, a proline-rich region possibly involved in Src-SH3 binding, the SH2 binding 
phosphotyrosine residues 31 and 118. The C-terminal region containing four LIM domains  
responsible for focal adhesion targeting and binding to the phosphotyrosine phosphatase 
PTP-PEST microtubule protein tubulin (Brown et al., 1998; Cote et al., 1999; Herreros et a., 
2000; Schaller and Parsons, 1995; Tumbarello et al., 2002; Turner, 2000).   
Importantly, phosphorylation of paxillin at Y31 and Y118 mediates the interaction with Crk 
and p120RasGAP (Schaller and Parson, 1995; Tsubouchi et al., 2002). These interactions 
are associated with cytoskeletal regulation through modulation of the Rho GTPases, Rac1 
and RhoA respectively, and appear to perform cell specific roles in regulating integrin 
signaling and migration (Lamorte et al., 2003; Petit et al., 2000).  Phosphorylation of paxillin 
at S85 and Y31 and Y118 regulates cell migration (Huang et al., 2004; Petit et al., 2000). The 
LD4 motif serves as a binding site for a number of signaling molecules, including focal 
adhesion kinase (FAK), G-coupled receptor kinase-interacting protein 1 (GIT1) and p95 
paxillin-kinase linker (PKL) (Horwitz et al., 2005). Extracellular signal-regulated kinase (ERK), 
has recently been shown to localize to adhesions and to regulate paxillin disassembly 
(Fincham et al., 2000; Webb et al., 2004).   
Paxillin is the founding member of a family of related proteins that now contains three 
members, paxillin, hic-5 and leupaxin. Hic-5 is 57% identical to paxillin and contains an 
organization of N-terminal LD motifs and C-terminal LIM domains similar to paxillin. Hic-5 
localizes to focal adhesions and shares a number of binding partners with paxillin including 
FAK (Hagmann et al., 1998; Thomas et al., 1999; Ishino et al., 2000) and syndecan-4. 
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Leupaxin exhibits 37% identity with paxillin and contains the same domain organization as 
paxillin with N-terminal LD motifs and four C-terminal LIM domains (Lipsky et al., 1998). As 
expected from the sequence observation, leupaxin can associate with anumber of the same 
proteins that can bind paxillin including the FAK-related protein, Pyk2 (Lipsky et al., 1998). It 
is anticipated that some of the functions of paxillin, hic-5 and leupaxin overlap given the high 
degree of sequence identity within the LD motifs and LIM domains. However, within the N-
terminal domains of these proteins there are regions of sequence divergence, suggesting 
that each protein might also perform unique functions. The phenotype of the paxillin-/- mice 
closely resembles that of fibronectin-/- mice, suggesting that paxillin is a critical transducer of 
signals from fibronectin receptors during early development (Hagel et al., 2001).  
 
   
 
Fig. 5: Paxillin binding partners.  
Paxillin is comprised of multiple protein binding motifs, including the amino-terminal LD motifs, the 
carboxy-terminal LIM domains, and several phosphotyrosine-SH2 domain docking sites. These range 
from structural actin binding proteins including actopaxin and vinculin to important signalling molecules 
such as FAK (focal adhesion kinase), ILK (integrin-linked kinase), and PTP-PEST, a tyrosine 
phosphatase. Many other potential paxillin binding partners have been identified in coprecipitation 
experiments, although in many cases it remains to be determined whether the interaction with paxillin is 
direct and which domain of paxillin is involved.  
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Syndesmos is a cytoplasmic protein that interacts specifically with the cytoplasmic domain of 
syndecan-4, and co-localizes with syndecan-4 in focal contacts. The interaction of 
syndesmos involves both the C1 and the V subdomains of the cytoplasmic domain of 
syndecan-4 (Baciu et al., 2000). Syndesmos is ubiquitinously expressed and can be 
myristylated. Denhez et al., (2002) found that syndesmos interacts with the focal adhesion 
adaptor protein paxillin in a direct manner and also binds the paxillin homolog Hic-5. These 
interactions are triggered by the activation of protein kinase C (PKC). The connection of 
syndecan-4 with paxillin through syndesmos parallels the connection between paxillin and 
integrins and may thus reflect the cooperative signaling of these two receptors in the 
assembly of focal adhesions and actin stress fibers. When overexpressed in NIH3T3 cells, 
syndesmos accelerates cell spreading, enhances the assembly of actin stress fibers and 
focal adhesion formation in a serum-independent manner (Baciu et al., 2000).   
 
1.4 Activated downstream signaling cascades 
 
1.4.1 Enzyme-linked receptors 
 
Receptor mediated signaling can occur through two different types of transmembrane 
receptors, the enzyme-linked and G-protein-linked cell-surface receptors. Enzyme-linked 
receptors are transmembrane proteins and five classes have thus been identified: receptor 
tyrosine kinases, tyrosine-kinase-associated receptors, receptor serine/threonine kinases, 
transmembrane guanylyl cyclases and histidine-kinase-associated receptors. The 
extracellular signals that act through receptor tyrosine kinases (RTKs) consists of a large 
variety of secreted growth factors and hormones including epidermal growth factor (EGF), 
platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), insulinlike growth 
factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) amongst others. Ligand 
binding to RTKs induces the receptors to cross-phosphorylate their cytoplasmic domains on 
multiple tyrosines. The autophosphorylation activates the kinases, as well as producing a set 
of phosphotyrosines that then serve as docking sites for a set of intracellular signaling 
proteins, which bind via their SH2 (Src homology region) domains. Some of the receptor-
bound proteins serve as adaptors to couple the receptors to the small GTPase Ras, which, in 
turn, activates a cascade of serine/threonine phosphorylations that converge on a MAPK, 
which relays the signal to the nucleus by phosphorylating gene regulatory proteins there. Ras 
can also activate another protein that docks on activated RTKs, PI3K (phosphatidylinositol 3-
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kinase), which generates specific inositol phospholipids that serve as docking sites in the 
plasma membrane for signaling proteins with pleckstrin homology domains (PH), including 
PKC (protein kinase B). 
 
1.4.2 G protein-coupled receptors (GPCR) 
 
G protein-coupled receptors (GPCRs), also known as seven transmembrane receptors, are a 
large family of transmembrane receptors that sense molecules outside the cell and activate 
inside signal transduction pathways. The extracellular loops contain two highly conserved 
cysteine residues which build disulfide bonds to stabilize the receptor structure. The G 
proteins are attached to the cytoplasmic face of the plasma membrane. There are various 
types of G proteins, e.g. the stimulatory G protein (Gs), which activates adenyl cyclase and 
thereby increases cyclic AMP concentration; the inhibitory G protein (Gi), which inhibits 
adenyl cyclase, but it mainly acts by directly regulating ion channels; and G protein Gq, 
which in turn activates phospholipase C-β. All G-proteins have the same structure and 
operate in a similar way. G proteins are composed of three protein subunits, α, β and γ. In 
the unstimulated state, the α subunit has GDP bound and the G protein is inactive. When 
stimulated by an activated receptor, the α subunit, which is a GTPase, releases its bound 
GDP, allowing GTP to bind in its place. This exchange causes the trimer to dissociate into 
two activated components, an α subunit and a βγ complex. GTP binding causes a 
conformational change that affects the surface of the α subunit that associates with the βγ 
complex in the trimer. The GTPase activity of the α subunit is greatly enhanced by the 
binding of a second protein, a regulator of G protein signaling (RGS), which acts as GTPase 
activating protein (GAPs). Activated G-protein-linked receptors themselves are 
phosphorylated by G-protein-linked receptor kinases (GRKs), which uncouple the receptors 
from G proteins and promotes receptor endocytosis. Some G-protein-linked receptors either 
activate or inactivate adenyl cyclase, thereby altering the intracellular concentration of the 
mediator cAMP. Others activate a phosphoinositide-specific phosphplipase C (PLCβ), which 
hydrolyzes phosphatidylinsositol 4,5-biphosphate (PIP2). Protein kinase C and A (PKC and 
PKA) and Ca2+/calmodulin-dependent protein kinase (CaM-kinase) phosphorylate specific 
target proteins on serine or threonines and thereby alter the activity of the proteins. One of 
this downstream phophorylations lead to the induction of the activation of myosin light chain 
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1.4.3 MAPK and JNK signaling pathway 
 
Mitogen-activated protein kinases (MAPKs) are important signal transducing enzymes that 
are involved in many facets of cellular regulation. MAPKs phosphorylate specific serines and 
threonines of target protein substrates and regulate cellular activities ranging from gene 
expression, mitosis, movement, metabolism, and programmed cell death (Johnson and 
Lapadat, 2002). MAPK activity is regulated through three-tiered cascades composed of a 
MAPK, MAPK kinase (MAPKK, MKK or MEK) and a MAPKK kinase or MEK kinase 
(MAPKKK or MEKK) (English, 1999). There are at least four distinctly regulated groups of 
MAPKs expressed, extracellular signal-related kinases (ERK1/2), c-Jun amino-terminal 
kinases (JNK1/2/3), p38 proteins (p38α/β/γ/δ) and ERK5. These MAPKs  are activated by 
specific kinases, MAPKKs : MEK1/2 for ERK1/2, MKK3/6 for the p38 proteins, MKK4/7 for 
the JNKs, and MEK5 for ERK5 (Chang and Karin, 2001).  
ERK1 and ERK2 are widely expressed and are involved in the regulation of meiosis, mitosis, 
and postmitotic functions in differentiated cells. Many stimuli, including growth factors, 
cytokines, virus infection, ligands for heterodimeric guanine nucleotide-binding protein (G-
protein)-coupled receptors, transforming agents, and carcinogens, activate the ERK1 and 
ERK2 pathways. Both are components of a three-kinase phospho-relay module which can be 
activated by the proto-oncogene Ras. Oncogenic Ras persistently activates the ERK1 and 
ERK2 pathway through the MAPKKK activity of Raf-1, which phosphorylates and activates 
MEK1/2. MEK1/2 finally activate ERK1/2 by phosphorylation of threonine and tyrosine 
residues in the regulatory Thr-Glu-Tyr (TEY) motif (Robinson and Cobb, 1997). This 
contributes to an increased proliferative rate of tumor cells. For this reason, inhibitors of the 
ERK pathway are entering clinical trials as potential anticancer agents. 
The JNKs were discovered to bind and phosphorylate the DNA binding protein c-Jun and 
increase its transcriptional activity. Regulation of the JNK pathway is extremely complex and 
is influenced by 13 MKKKs that regulate the stimuli of JNKs. JNKs are important in 
controlling programmed cell death or apoptosis (Tournier et al., 2000). Inhibition of JNKs 
enhances chemotherapy-induced inhibition of tumor cell growth, suggesting that JNKs may 
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1.4.4 Endothelin-induced signaling cascade 
 
Endothelins are a family of small, structurally related, vasoactive peptides that have a great 
number of physiological roles in many tissues. The ‘endothelin axis’ consitsts of three 21 
amino acid peptides (ET1, ET2 and ET3), two G-protein-coupled receptors EDNRA and 
EDNRB, and two activating peptidases or endothelin-converting enzymes (ECE-1 and ECE-
2). The three endothelin peptide isoforms derive from three separately regulated genes yet 
having a similar structure (Inoue et al., 1989). The gene for each endothelin has a distinct 
pattern of tissue expression: ET1 is expressed primarily by endothelial cells, ET2 in epithelial 
cells of the kidney and intestine, and ET3 is found in the brain (Saida et al., 2000). 
Endothelins and their receptors are also expressed by `mobile´ inflammatory cells such as 
monocytes and macrophages (Grimshaw et al., 2002; Ehrenreich et al., 1990). Binding of the 
ligands to their receptors, EDNRA and B, which are coupled to the Gs and Gq/11 proteins 
(Landry et al., 2005), may modulate several overlapping signalling pathways (Fig. 6). ET1 
receptors can activate RhoA through the heterotrimeric G-protein α-subunits Gα13 (Hersch et 
al., 2004) and Gα13/Gαq (Mao et al., 1998; Yuan et al, 2001), respectively. The EDNRA is 
highly specific for ET1, whereas EDNRB also binds ET1, ET2, and ET3 with similiar affinity 
(Rubanyi and Polokoff, 1994).       
Numerous tumors, including carcinomas of the lung (Ahmed et al., 2000), prostate (Nelson et 
al., 2000) and ovary (Bagnato et al., 1999) produce one or more of the endothelins and their 
receptors (Nelson et al., 2003). Endothelins play an autocrine and paracrine role in regulating 
growth of seceral tumor types and may also inhibit apoptosis (Grimshaw et al., 2002) and 
promote angiogenesis (Bagnato et al., 2002).  
However, the actions of endothelins in cancer are unclear and appear to be tumor-specific. In 
prostate cancer, EDNRB is decreased or absent (Kopetz et al., 2002) and there is often 
methylation of the EDNRB gene (Nelson et al., 1997), while in lung cancer, EDNRA is down-
regulated (Ahmed et al., 2000). ET1 enhances the secretion of MMPs, disrupts intracellular 
communications, and stimulates cell migration (Rosano et al., 2006). In ovarian carcinoma 
cells, where ET1 and EDNRA are overexpressed, ET1 induces loss of adherens and tight-
junction protein expression, E-cadherin, beta-catenin, and gain of N-cadherin and vimentin 
expression. These results confirm the ability of ET1 to promote EMT, a metastable process 
involving sustained loss of epithelial markers and gain of mesenchymal markers. These 
findings provide evidence for a critical role for the ET1/EDNRA axis during distinct steps of 
ovarian carcinoma progression (Rosano et al., 2006).  
In contrast to ovarian cancer with a high EDNRA expression, EDNRB is overexpressed in 
human cutanous melanomas, where it promotes tumorigenesis upon activation by ET1 or 
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ET3, thus representing a potential novel therapeutic target (Spinella et al., 2007). Spinella et 
al. (2007) showed that under normoxic conditions, EDNRB activation by ET1/ET3 enhances 
vascular endothelial growth factor (VEGF) up-regulation, cyclooxigenase (COX)-1/COX-2 
protein expression and COX-2 promotor activity, prostaglandin E(2) (PGE(2)) production, 
and do so to a greater extent under hypoxia. These results identify a new mechanism 
whereby ET1/ET3/EDNRB axis can promote and interact with the HIF-1alpha-dependent 
machinery to amplify the COX-mediated invasive behaviour of melanoma cells (Spinella et 
al., 2007).  
 
         
 
 
Fig. 6: ET1-induced signal transduction pathways in ovarian cancer cells.  
Binding of ET-1 to EDNRA/EDNRB triggers signal transduction pathways through a pertussis-
insensitive G protein that is coupled to the EDNRA/B intracellular domain. Activation of 
phospholipase C (PLC), protein tyrosine kinases (PTKs; such as FAK and paxillin) ultimately 
results in the activation of the RAF/MEK/MAPK pathway. ET1 also causes Src-mediated 
epidermal growth factor receptor (EGFR) transactivation that is in part responsible for MAPK 
activation. ET1 also stimulates phosphatidylinositol 3-kinase (PI3K)-mediated Akt activation. 
Parallel mobilization of intracellular calcium (Ca2+), activation of protein kinase C (PKC), MAPK 
and Akt induces nuclear transcription of genes, such as VEGF, ET1, COX-1 and 2, leading to 
proliferation, survival, angiogenesis and invasion. Further analysis showed that ET1 promotes 
cyclooxigenase (Cox)-1 and -2 expression and, in turn, prostaglandine (PG) E2 production, and 
amplifying ET1 driven VEGF production. DG, Diacylglycerol; IP3, inositol 1, 4, 5 triphosphate; 
MAPK, mitogen activated protein kinase; mTOR, mammalian target of rapamycin; MEK, MAPK 
kinase; p125 FAK, focal adhesion kinase; PLA, phospholypase A; VEGF, vascular endothelial 
growth factor.  
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1.4.5 Lysophosphatidic acid (LPA) 
 
Lysophosphatidic acid (LPA), which is generated from precursors in the plasma membrane, 
has numerous cellular effects including cell proliferation, calcium homeostasis, cytoskeleton 
reorganization, cell adhesion and migration, and ion transport regulation (Moolenaar, 1999; 
van Leeuwen et al., 2003; Sengupta et al., 2004). LPA is a serum-borne phospholipid with 
hormone and growth factor-like properties and has been shown to modulate tumor cell 
invasion and malignant cell growth (Stähle et al., 2003). LPA exerts its biological activities 
through its interaction with four identified LPA receptors, namely LPA1, LPA2, LPA3, LPA4, 
which additionally activate the Gi, G12/13 and Gq subfamilies of G proteins (Fig. 7) (Moolenaar 
et al., 2004). While LPA1 is expressed ubiquitously, recent studies have shown that the levels 
of LPA2 and LPA3 are elevated in various tumors such as ovarian, colon, breast and prostate 
cancers (Daaka, 2002; Fujita et al., 2003) Kitayama et al., 2004; Shida et al., 2004). LPA can 
promote the expression/activation of various invasion-associated proteases including 
metalloproteinases in ovarian cancer cells (Pustilnik et al., 1999; Fishman et al., 2001) and 
enhances proangiogenic factor production (VEGF, IL-6 and 8) by ovarian cancer cells 
(Schwartz et al., 2001; Hu et al., 2003). LPA activates Rac1 to promote cell spreading, 
lamellipodium formation and cell migration in fibroblasts (van Leeuwen et al., 2003), as well 
as RhoA through the G12/13 subunits of G proteins (Kranenburg et al., 1999; Yuan et al., 
2003). Bian et al. (2005), have shown that G12/13-, but not Gq-associated signaling pathway 
mediated LPA-induced focal adhesion kinase (FAK) autophosphorylation and was important 
for efficient LPA-stimulated cell migration. Furthermore, LPA-induced ERK activation results 
in a transient translocation of the phosphorylated ERK to newly forming focal contact sites at 
the leading edge of the migrating cell (Stähle et al., 2003).       
It has been shown that LPA-induced microtubule (MT) rearrangement was accompanied by 
accumulation of myosin IIB and polymerized actin at the base of retraction fibers. Fukushima 
and Morita, 2006, showed that LPA did not induce MT depolymerization and that LPA-
induced actomyosin activation produced MT and neurofilament rearrangement, leading to 
neurite remodelling.  
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1.4.6 PI3K-Akt/PKB pathway 
 
The signals set off by phosphoinositide 3-kinase (PI3K) a
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PI3K/PKB/TOR axis controls protein synthesis and growth, while PIP3-mediated activation of 
Rho GTPases directs cell motility. PI3K activity has been linked to the formation of tumors, 
metastasis, chronic inflammation, allergy and cardiovascular diseases (Wymann and 
Marone, 2005). 
 
1.4.7 PDGFR signaling 
 
Platelet-derived growth factor (PDGF) exerts its stimulatory effects on cells by binding to two 
related protein tyrosine kinase receptors, PDGFRα and PDGFRβ. PDGF is a potent 
stimulator of growth and motility of connective tissue cells, such as fibroblasts and smooth 
muscle cells, but also for capillary endothelial cells and neurons (Zhang and Hutchins, 1997). 
It has important roles during embryonic development and in the adult. PDGF stimulates 
wound healing (Hanaoka et al. 2006) and has an important role in the maintenance of the 
interstitial fluid pressure (Heldin et al., 2004). Moreover PDGF has been implicated in the 
regulation of the tonus of blood vessels.  
  
PDGF is a dimeric molecule consisting of disulfide-bonded A-and B-polypeptid chains. 
Homodimeric (PDGF-AA, PDGF-BB) as well as heterodimeric (PDGF-AB) isoforms exert, as 
well as the new identified isoforms C and D, that signal through the α and β receptor 
(PDGFR). The two receptors bind the PDGF isoforms with different affinities. The β-receptor 
binds PDGF-BB with high affinity (Kd, 0.5 nm) and PDGF-AB with lower affinity (Kd, 2.5 nm), 
but there is no appreciable affinity for PDGF-AA. The α-receptor binds all three PDGF 
isoforms with similar affinities (Claesson-Welsh, 1994). Ligand binding induces receptor 
dimerization and autophosphorylation, allowing binding and activation of cytoplasmic SH2-
domain containing signal transduction molecules. PDGF-AA induces α-α homodimers, 
PDGF-AB induces α-α homodimers and α-β heterodimers, and PDGF-BB form all three 
types (α-α, α-β and β-β) of dimers. Dimerization of the receptors is the key event in PDGF 
receptor activation, which then allows phosphorylation in trans between the two receptors in 
the complex. One of the most important autophosphorylation sites, Y857, is located inside 
the kinase domain. More than 10 different SH2-domain-containing molecules have been 
shown to bind different autophosphorylation sites in the PDGF α- and β-receptors, including 
signal transduction molecules with enzymatic activity, such as PI3K, PLCγ, the Src family of 
tyrosine kinases, the tyrosine phosphatase SHP-2, GAP of Ras, as well as adaptor 
molecules such as Grb2, Shc, Nck, Grb7 and Crk and Stat5 (Fig. 8). Thereby, Ras-Raf-
ERK/MAPK, PI3K-Akt/PKB and PLCγ signaling pathways are initiated leading to cell growth, 
actin reorganization, migration and differentiation.  
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Fig. 8: Interaction between PDGF α- and β-receptors and SH2-domain containing signal 
transduction molecules. The intracellular part of homodimeric complexes of α- and β-
receptors are depicted.  
All tyrosine residues outside the catalytic domains and their numbers are indicated; known 
autophosphorylation sites are indicated by an encircled P. The conserved tyrosine residues in 
the kinase domains which are involved in the regulation of the catalytic activities are also 
indicated. The known interactions between individual phosphorylated tyrosine residues and 
different SH2 domain containing signal transduction molecules are shown.  








Recent observations suggest that extensive cross-talk occurs between different signaling 
pathways downstream of activated PDGFR, and that stimulatory signals are modulated by 
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Fig. 9: Schematic illustration of certain signaling pathways that are initiated by PDGF and 





One of the most common alterations in glioblastomas is the PDGF autocrine signaling, which 
is characterized by coexpression of PDGF and its receptor. Lokker and colleages showed 
2002 low expression of PDGF-A,-C,-D, PDGFRα and β in the T98G cell line, but no 
expression of PDGF-B. In contrast to the T98Gs and other glioma cell lines, an increased 
expression of all PDGF isoforms and their receptors were found just in the A172, U251 and 
SF188 glioma cell lines. In contrast, Takeuchi et al.(1994) have shown high levels of PDGF-A 
and –B in malignant glioma cell lines U87-MG, D54 and T98G. The cooexpression of PDGF 
and its receptor is frequently detected in a variety of tumors including malignant glioma 
(Maxwell et al., 1990; Hermanson et al., 1992; Guha et al., 1995), lung cancer (Antoniades et 
al., 1992), and sarcoma (Smits et al., 1992), suggesting the existence of a PDGF autocrine 
loop. The more recently identified PDGF isoforms, PDGF-CC and –DD, have been implied in 
autocrine glioma signaling (LaRochelle et al., 2002; Lokker et al., 2002). Paracrine 
stimulation by PDGF can effect tumor stroma recruitment and growth, as evidenced by 
studies showing an increased rate or incidence of tumor formation upon transfection of 
PDGF into receptor-negative tumor cell lines (Forsberg et al., 1993; Skobe and Fusenig, 
1998).  
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1.4.8 EGFR signaling 
 
The epidermal growth factor receptor (EGFR) signaling pathway is one of the most important 
pathways that regulate growth, survival, proliferation and differentiation in mammalian cells. 
Following the identification of EGFR (ErbB1), three additional members of the same receptor 
family were identified, ErbB2, ErbB3, and ErbB4, which belong to the receptor tyrosine 
kinases (RTKs). Like all RTKs, this family is composed of an extracellular ligand binding 
domain, followed by a single transmembrane domain and a cytoplasmic domain containing a 
conserved protein tyrosine kinase (PTK) core, flanked by regulatory sequences 
(Schlessinger, 2002). The extracellular domaine is composed of four subdomains designated 
domain I, II, III, and VI or L1, S1, L2 and S2, respectively (Lax et al., 1989). Growth factor-
induced receptor dimerization is followed by intermolecular autophosphorylation of key 
tyrosine residues in the activation loop of the catalytic PTK domain resulting in stimulation of 
its activity. Each dimeric receptor complex initiates a distinct signaling pathway by recruiting 
different SH2-containing effector proteins. Activated EGFR dimer complexes with the adaptor 
protein Grb2/Sos-1 complex can bind directly to phosphotyrosine sites in the receptor or 
indirectly through Shc, which brings it into vicinity to Ras, allowing for its activation, followed 
by induction of ERK and JNK signaling pathways. Furthermore, the activation of EGFR leads 
to binding of PLCγ and PI3K as well. Activating mutations and overexpression of members of 
the EGFR family were implicated in a variety of cancers, including mammary carcinomas, 
squamous carcinomas, and glioblastomas, as well as other malignant diseases (Blume-
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1.4.9 PLC signaling 
 
The phosphatidylinositol-specific phosphplipase (PLC) family is a group of critical cellular 
signaling enzymes that hydrolyze PIP2 to generate PIP3 and diacylglycerol, which increase 
the intracellular free Ca2+ concentration ([Ca2+]i) and activate protein kinase C (PKC), 
respectively (Rhee, 2001; Rebecchi et al., 2000). Eleven isoforms of PLC, representing five 
distinct, differentially regulated classes, have been identified: PLCβ1 to β4; PLCγ1 and γ2; 
PLCδ1, δ3 and δ4; and PLCε and PLCζ.  PLCβ is regulated by G-protein-coupled receptor 
(GPCR) activation of heterotrimeric Gq family G-proteins and Gβγ subunits. PLCγ is regulated 
by tyrosine phosphorylation by receptor tyrosine kinases (e.g. EGF, PDGF) and nonreceptor 
tyrosine kinases (e.g. Src) activated by immunoglobulins and cytokines. Regulation of PLCδ 
is less well understood but is propably regulated by changes in [Ca2+]i, possibly downstream 
from activation of other PLC isoforms, and by high molecular weight G-protein, Gh. PLCζ is 
also regulated by [Ca2+]i (Kouchi et al., 2003). PLCε was discovered only recently and is the 
largest member of the PLC family (Kelley et al., 2001; Lopez et al., 2001; Song et al., 2001; 
Kelley et al., 2005). PLCε is regulated by the monomeric Ras (Song et al., 2002; Kelley et al., 
2004) and Rho (Kelley et al., 2004; Seifert et al., 2004) families, the heterotrimeric G12 
family and Gβγ subunits (Wing et al., 2001). Receptor tyrosine kinase agonists, EGF and 
PDGF have been shown to stimulate PLCε through Ras and Rap (Kelley et al., 2006). 
GPCR-mediated activation of PLCε by LPA occurs through Gα12/13 and Rap (Kelley et al., 
2004). The GPCR agonist, endothelin and LPA activate both endogeneous PLCε and PLCβ3 
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1.4.10 The proteasome pathway 
 
Protein degradation via the proteasome is often deregulated in tumors (Spataroet al., 1998; 
Piva et al., 1999; Kato, 1999). One of the novel therapeutic targets for resistant tumors is the  
ubiquitin/proteasome pathway (Fig. 10.), a key element in cell cycle progression and cell 
survival (Krek, 1998; Peters, 1999; Li and Dou, 2000; MacFarlane et al., 2002; Suzuki et al., 
2001; Podust et al., 2000). Proteasome inhibition is very promising in controlling cell cycle 
and inducing apoptosis (Laurent et al., 2003), and an attractive target for anticancer therapy 
(Kisselev and Goldberg, 2001; Adams, 2002).    
 
 
             
 
Fig. 10: Protein degradation through the ubiquitin (Ub)-proteasome pathway.  
Most proteins that are destined for degradation through the Ub-proteasome pathway are first 
subjected to ubiquitination. This is accomplished in several stages. The E1 Ub-activating 
enzyme, is an ATP-dependent reaction, forms an activated complex with Ub and transfers it 
to the E2 Ub-conjugating protein. The E2 Ub-conjugating protein then transfers Ub to an E3 
Ub-ligase protein, which has formed a complex with the target protein. In some cases an E3 
Ub-ligase may not be necessary. After several cycles of ubiquitination, the polyubiquitinated 
target protein is recognized by the proteasomal cap proteins through its ubiquitin moieties, 
which are cleaved off by isopeptidases and recycled. In an ATP-dependent fashion the 
protein is then unwound and fed into the 20S core through an interior channel, where it is 
exposed to the active proteolytic enzymes. Oligopeptide digestion products are then released 
and degraded further to amino acids by oligopeptidases. Some proteins may be subject to 
proteasomal degradation without the need for prior ubiquitination (Orlowski et al, 2003; 











Receptor degradation is preceded by ubiquitination and was blocked by proteasome 
inhibitors. C-Cbl, one of the numerous proteins that bind to the PDGFR (Bonita et al., 1997), 
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has recently been identified as a proteasomal E3-like ubiquitin ligase that is involved in 
down-regulation of tyrosine kinase receptors (Levkowitz et al., 1999; Joazeiro et al., 1999; 
Yokouchi et al., 1999). Decreased PDGFR levels in suspended cells correlated with 
ubiquitination of the PDGFR and was blocked by treatment with inhibitors of the proteasome 
pathway. Baron and Schwartz (2000), conclude that cell detachment results in cellular 
desensitization to PDGF that is mediated by degradation of the PDGFR via a novel ubiquitin-
dependent pathway.  
PDGF induced Src-dependent association between the multifunctional 
transcription/translation regulator hnRNP-K and the mRNA-encoding myosin regulatory light-
chain (MRLC)-interacting protein (MIR), an E3-ubiquitin ligase that is MRLC specific. Down-
regulation of MIR by RNA muting prevented the reorganization of actin structures and 
severely reduced the migratory and wound-healing potential of PDGF-treated cells. The 
PDGF-induced protein destabilization through the regulation of hnRNP-K controlled ubiquitin-
ligase translation identifies a novel pathway by which external stimuli can regulate 
phenotypic development through rapid, organelle-specific changes in the activity and stability 
of cytoskeletal regulators (Nagano et al., 2006).  
It has been reported that the small GTPase RhoA is targeted for degradation at the leading 
edge of migrating cells by the E3 ubiquitin ligase Smurf1, and that this is required for the 
formation of protrusions. Sahai et al. (2007), report that Smurf1-dependent RhoA 
degradation in tumor cells results in the downregulation of Rho kinase (ROCK) activity and 
myosin light chain2 (MLC2) phosphorylation at the cell peripherie. Smurf1 regulates cell 
polarity and protrusive activity via PKCζ-dependent recruitment to cellular protrusion sites, 
and subsequent ubiquitination and proteasomal degradation of RhoA in HEK293T cells 
(Zhang et al., 2004; Wang et al., 2003). This targeting leads to the activation of Rac1 and 
Cdc42, and the formation of membrane microspikes. Thus, Smurf1 generates an intracellular 
asymmetry of GTPase activity, thereby regulating cell polarity and cytoskeleton 
rearrangements (Bryan et al., 2005). In contrast, phosphorylation of Ser188 of RhoA protects 
RhoA, particulary its active form, from ubiquitin-mediated proteasomal degradation. This 
phosphorylation is induced by cAMP-dependent protein kinase (PKA) and c-GMP-dependent 
protein kinase (PKG), causing their relocalization in the cytosol (Lapetina et al., 1989; 
Quilliam et al., 1991; Lang et al., 1996). Results of Rolli-Derkinderen et al., 2005, suggest 
that Ser188 phosphorylation-mediated protection against degradation is a physiological 
process regulating the level of endogenous RhoA and this may define a novel function of 
RhoGDI, as an inhibitor of Rho protein degradation (Forget et al., 2002).  
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1.5  The actin cytoskeleton 
 
The cytoplasm of eukaryotic cells is spatially organized by a network of protein filaments 
known as the cytoskeleton. This network contains three principal types of filaments. 
Intermediate filaments provide mechanical strength and resistance to shear stress. 
Microtubules, long hollow cylinders made of the protein tubulin, determine the position of 
membrane-enclosed organelles and direct intracellular transport. Actin filaments are most 
concentrated just beneath the cell membrane, and are responsible for resisting tension and 
maintaining cellular shape, forming cytoplasmic protuberances and participation in some cell-
to-cell or cell-to-matrix junctions. Around 5-9 nm in diameter, this filament is composed of 
two-stranded helical polymers of the protein actin. They appear as flexible structures, which 
are organized into a variety of linear bundles, two-dimensional networks, and three-
dimensional gels. Actin filaments have polarity and the actin monomers all orient with their 
cleft toward the same end of the filament (designated the minus end) and therefore they play 
a major role in cell migration.      
Cell structures that involve actin and are important for cell migration are filopodia, 
lamellipodia and pseudopodia. Filopodia contain a core of long and thin, bundled actin 
filaments, which are oriented toward the tip, out of the cell surface. Lamellipodia are two-
dimensional, dynamic sheet-like structures at the leading edge of a mobile cell. They contain 
an orthogonally cross-linked mesh of branched arrays of actin filaments, most of which lie in 
parallel to the solid substratum. Pseudopodia are stubby three-dimensional projections filled 
with actin-filament gel.   
The motor protein myosin II in stress fibers is responsible for their ability to contract. In 
contractile bundles, loose packing allows myosin II to enter the bundle, whereas in parallel 
bundles a tight packing prevents myosin II from entering the bundle. Another important actin-
filament binding protein is cofilin, which destabilizes actin filaments along their length, 
distorting the helical twist of filamentous actin.    
 
1.5.1 The Rho family GTPases 
 
For the actin cytoskeleton, global structural rearrangements in response to external signals 
are triggered through diverse cell-surface receptors. But all of these signals seem to 
converge inside the cell on a group of closely related monomeric GTPases. Rho GTPases 
comprise a large subfamily of the Ras superfamily and include Cdc42, Rac and Rho (Ras-
homologous) proteins, as well as Rnd and RhoBTB (Burridge and Wennerberg, 2004). They 
are guanine nucleotide binding proteins that cycle between an active, GTP-bound and 
inactive, GDP-bound state. The activity of Rho proteins is controlled by guanine nucleotide 
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exchange factors (GEFs) and GTPase-activating proteins (GAPs). In cells, Rho GTPases 
exist predominantly in their inactive form, in complex with GDP dissociation inhibitors (GDIs) 
(Malliri et al., 2003). Rho GTPases also capture and stabilize microtubules (MT) through their 
effectors (e.g. mDia and Par6) next to the cell cortex, leading to polarized cell morphology 
and directional cell migration (Fukata et al., 2003). Activation of Rho (RhoA, RhoB, RhoC) 
leads to assembly of actin-myosin filaments (stress fibers) and of associated focal adhesion 
complex. It acts as a molecular switch to control a signal transduction pathway that links 
membrane receptors to the cytoskeleton. Activated Rac (Rac1, Rac2, Rac3, RhoG) induces 
actin polymerization, followed by the assembly of a meshwork of actin filaments at the cell 
periphery to produce lamellipodia and membrane ruffles. Activation of Cdc42 (Cdc42, TC10, 
TCL, Wrch1, Chp/Wrch2) was shown to induce actin polymerization which leads to actin-rich 
surface protrusions called filopodia (Alan Hall, 1998).  
  
1.5.2 Rho/ROCK signaling pathway 
 
The first molecular explanation for how Rho affects the actin cytoskeleton came from the 
discovery that its downstream target ROCK (Rho kinase) phosphorylates and thereby inhibits 
the regulatory subunit of myosin light chain (MLC) phosphatase. ROCK can also directly 
phosphorylate MLC. In this way, it increases the level of phosphorylated MLC, which 
promotes interaction of myosin filaments with actin filaments and increases contractility 
(Amano et al., 1996; Ridley, 2001). Several cytoskeletal targets have also been identified 
downstream of ROCK, such as LIM kinase (LIMK). LIM kinase phosphorylates the actin 
depolymerising protein, cofilin/ADF, thus inhibiting its function (Maekawa et al., 1999). The 
inhibition of cofilin stabilizes actin filament arrays such as stress fibers and the cell cortex, 
and promoted focal adhesion formation (Fig. 11).  
In contrast, stress fibers could also be induced by coexpression of activated forms of the 
mammalian homolog of diaphanous (mDia), another Rho effector (Watanabe et al., 1999). 
Expression of activated forms of mDia promote assembly of fine arrays of thin stress fibers 
that appear to be less bundled than the stress fibers induced by Rho activation or expression 
of constitutively active ROCK (Burridge and Wennerberg, 2004).   
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Fig. 11: Signaling from Rho to the 
cytoskeleton. 
The pathways from Rho to the 
formation of actin stress fibers are 
described in the text. 
Direct activating signals are 
presented by solid arrows. Inhibitory 
signals are depicted as red bars. 
Double-lined arrows and bars 
represent the net result of a 
signalling pathway. 
Abbrevations used: LIMK, LIM 
kinase; MLC-P, phosphorylated 
myosin II regulatory light chain; MLC 
phosphatase, myosin light chain 
phosphatase. 





Actin filaments in most cells are stabilized by the actin binding molecule tropomyosin, which 
binds simultaneously to seven adjacent actin subunits in one protofilament. It plays the key 
role in the regulation of muscle contraction and comes in a rod-like form and binds to the 
groove of each side of double-helical actin filaments (Fig. 12) (Vilfan, 2001). Together with 
the associated protein troponin, tropomyosin on actin can switch between two laterally 
shifted conformations (Lehmann et al., 2000). The equilibrium between these two 
confirmations is strongly influenced by the concentration of Ca2+ ions.      
 There exist three isoforms of high molecular weight (HMW) tropomyosins, TM1, 2 and 3, as 
well as low molecular weight (LMW) isoforms TM4 and 5. In vertebrates, more than 10 
different isoforms of HMW tropomyosins are expressed from TPM1 (α-TM) and TPM2 (β-TM) 
genes, and by alternatively RNA splicing (Pittenger et al., 1994). The HMW tropomyosins are 
found along stress fibers and are thought to play a role in stabilizing the organization of actin 
filaments, which in turn plays an important role in the maintainance of cell shape, cell motility, 
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 Fig. 12: Visualization of interaction of tropomyosin and actin. 
A model of the arrangement of tropomyosin, actin and three troponin 
subunits (Tn) in a skeletal muscle thin filament . 
Note the adjacent tropomyosin molecules overlap head to tail with 
the N-terminus of Tn-T lying along the overlap region. The C-
terminus of Tn-T interacts with Tn-C and Tn-I, and Tn-I also 
interacts with actin. 
Tropomyosin a-subunit brown, b-subunit orange, actin grey,TnI 
green, TnC red, TnT yellow.  








In endothelial cells, oxidative stress quickly activates the MAPK, which results in the 
phosphorylation of tropomyosin. Houle et al. (2007), identified death-associated kinase 1 
(DAP kinase 1) as the kinase that phosphorylates TM1 in response to ERK activation by 
hydrogen H2O2. They also report that the phosphorylation of TM1 mediated by DAP kinase 
occurs on S283.  
Silencing of TMs with short interfering RNAs (siRNAs) blocks stress fiber assembly, whereas 
ectopic expression of TMs results in stress fibers. Ectopic expression and siRNA 
experiments showed that Smads mediate induction of TMs and stress fibers. TGF-β 
induction of TMs and stress fibers are significantly inhibited by Ras-ERK signaling in 
metastatic breast cancer cells. Inhibition of the Ras-ERK pathway restores TGF-β induction 
of TMs and stress fibers and thereby reduces cell motility. These results suggest that 
induction of TMs and stress fibers play an essential role in TGF-β control of cell motility, and 
the loss of this response is a critical step in the acquisition of a metastatic phenotype by 






                                                                                                                                                              Introduction 
                                                                                                                                                                                              
 
1.5.3.1 Tropomyosins in cancer 
 
One of the most prominent features of malignant cells is the presence of an altered actin 
cytoskeleton, arising from the suppression of several key actin-binding proteins, such as 
profiling, α-actinin, and tropomyosins (TMs) (Lin et al., 1997; Pawlak and Helfman, 2001). 
Tropomyosin isoform-1 (TM1) is consistently suppressed in breast cancer cell lines (Martin 
and Leder, 2001; Bhattacharya et al., 1990) and breast tumors (Raval et al., 2003), and is 
downregulated in urinary bladder tumors (Pawlak et al., 2004), suggesting that the loss of 
TM1 may contribute to neoplastic transformation. Restoration of TM1 expression in several 
oncogene-transformed (Prasad et al., 1993, 1999; Bravermann et al., 1996) and 
spontaneously transformed breast cancer cells (Mahadev et al., 2002; Raval et al., 2003) 
induces microfilaments, and actin stress fibers in a Rho-kinase-dependent fashion (Shah et 
al., 2001). This suppressed the anchorage-independent growth of the tumor cells. Further 
investigations have revealed that TM1 induces anoikis in breast cancer cells, and thus may 
suppress their malignant behavior (Mahadev et al., 2002; Raval et al., 2003). Since TMs 
stabilize the actin cytoskeleton (Cooper, 2002) and regulate actin-myosin interactions 
(Marston et al., 1998), Bharadwaj et al. (2004), have hypothesized that TM1-mediated 
cytoskeletal reorganization is critical for the antineoplastic effects of TM1. A tenascin-C 
induced downregulation of TM1 expression in T98G glioblastoma cells was observed by Ruiz 
et al. (2004). Pawlak et al.(2004), observed a high level of the isoform TM5 in four different 
transitional cell carcinoma (TCC) cell lines, whereas TM5 was expressed at very low levels in 
normal bladder mucosa.  
Bharadwaj and Prasad (2002), showed that hypermethylation of TM1 gene and chromatin 
remodelling are the predominant mechanisms by which TM1 expression is down-regulated in 
breast cancer cells. This finding indicates that hypermethylation and chromosomal 
compaction by histone deacetylation are major mechanisms by which TM1 expression is 
silenced in breast cancer cells. Thus, while the βTM gene is generally inactivated by gene 
methylation in cancer cells, it appears that down-regulation of αTM gene (which codes for 
TM2 and TM3) via promoter methylation may occurs upon transformation by ras. 
Suppression of HMW TMs, in particular that of TM1 and TM2 occur very rapidly, before the 
morphological transformation is evident, suggesting that the loss of TM1 may be an early 
event during tumorigenesis. Therefore, the loss of TM1 expression may serve as a potential 
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1.6 Cell migration 
 
Cell migration is a central process in the development and maintenance of multicellular 
organisms, which involves rapid changes in the dynamics of actin filaments, together with the 
formation and disassembly of cell adhesion sites (Brakebusch, C and Fassler, R, 2003). 
Tissue formation during embryonic development, wound healing and immune responses all 
require the orchestrated movement of cells in a particular direction to a specific location. The 
migration process consists of four different steps, polarization, protrusion, traction and 
retraction. A polarized cell has distinct leading and trailing edges, which is a common feature 
of both fibroblastic and amoeboid motility. The leading edge points in the direction of 
movement and is driven by actin-polymerization-mediated protrusion. There are two main 
types of nucleators of actin polymerization: the Arp2/3 complex (actin-related proteins) and 
the formins mDia1 and mDia2. Cell polarity, which is essential for directed migration, is 
defined not only by actin-mediated protrusions but also by reorientation of the MTOC 
(microtubule-organizing center) towards the leading edge. Cdc42 regulates MTOC 
positioning through Par proteins and PKCζ (Jaffe and Hall, 2005).  
Arp2/3 binds to the sides of existing actin filaments and promotes the extension of a new 
actin filament from its pointed end, forming a 70° angle with pre-existing filament (Weaver et 
al., 2003). Arp2/3 regulation is controlled by WAVE/Scar, WASP and N-WASP proteins. This 
complex is under the control of the small GTPase Rac. Unlike the Arp2/3 complex, formins 
bind to the barbed end of actin filaments and promote actin growth in a linear fashion 
(Watanabe and Higashida, 2004).  
Actomyosin-based contraction is controlled by the small Rho GTPases Cdc42, Rac and 
RhoA (Jaffe and Hall, 2005). This contraction is provided the action of integrins in adhesions 
and tractional force is created at sites of adhesion by myosin II interactions with actin 
filaments. During migration, adhesions assemble at the leading edge and disassemble at the 
trailing edge. However, adhesions also disassemble at the front during protrusion and feed 
components to nascent adhesions at the leading edge in a process called adhesion turnover 
(Webb et al., 2004). Among the structural molecules, talin directly links integrins to actin and 
also activates them (Nayal et al., 2004). Rho GTPases are critical effectors in this process.       
For cells to translocate forward, adhesions at the rear must disassemble and the trailing 
edge needs to retract. Several mechanisms promote disassembly; these include 
microtubule-dependent targeting of dynamin and subsequent endocytosis of some adhesion 
components (Ezratty et al., 2005); myosin-mediated contractility contributes through 
regulation of MLC phosphorylation by RhoA and Rac acting through Rho-kinase and PAK. 
Finally, dissolution of the adhesive contacts at the rear edge is also achieved through affinity 
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downregulation by phosphorylation by phosphatases, such as calcineurin, or simply by 
proteolysis of molecules such as talin by the proteases calpain (Franco et al., 2004).  
 
1.6.1 Cell migration in cancer  
      
Errors during this process have serious consequences, including mental retardation, vascular 
disease, tumor formation and metastasis. Cancer cells migrate as single cells or in small 
groups to spread from the initial site of tumor growth. They acquire an invasive phenotype 
characterized by both the loss of cell-cell interactions and increased cell motility. These cells 
are able to enter the blood or lymphatic vessels (intravasation) and to cross the vessel wall to 
exit the vasculature in distal organs where they can continue to proliferate forming a second 
tumor. Cancer cell migration is typically regulated by integrins, matrix-degrading enzymes, 
and cell-cell adhesion molecules. Several cytokines and growth factors have been shown to 
stimulate invasion and to be upregulated in a variety of tumor types. An understanding of the 
mechanism by which cells migrate may lead to the development of novel therapeutic 
strategies for controlling invasive tumor cell. 
 
1.6.1.1 LPA in cancer cell migration   
  
Lysophosphatidic acid (LPA) has numerous cellular effects including cell proliferation, 
cytoskeleton reorganization, cell adhesion and migration (Moolenaar 1999, Sengupta et al., 
2004). LPA activates Rac1 to promote cell spreading, lamellipodium formation and cell 
migration in fibroblasts (van Leeuwen et al., 2003a). In pancreatic tumor cells, Erk activation 
is indicated to play a critical role for LPA-stimulated cell migration (Strähle et al. 2003). 
Further LPA-induced squamous cell carcinoma motility is mediated by EGF receptor 
transactivation (Gschwind et al., 2002). LPA can promote the expression/activation of various 
invasion-associated proteases such as metalloproteinases in ovarian cancer cells (Pustilnik 
et al., 1999; Fishman et al., 2001). Thus, these metalloproteinases cleave extracellular matrix 
molecules such as fibronectin, which greatly facilitates cancer cell migration.  
Bian et al. (2006) found that the G12/13 pathway was required for LPA-induced FAK 
autophosphorylation and efficient cell migration. Their studies showed that the G12/13-RhoA-
ROCK signaling pathway mediates LPA-induced FAK autophosphorylation and contributes to 
LPA-stimulated cell migration. They also showed that the disruption of the Gi-Ras-MEKK1 
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1.6.1.2 PDGF in cancer cell migration  
  
PDGF triggers rapid disassembly of focal adhesions and subsequent reassembly, the so 
called focal adhesion turnover, and continued adhesion assembly in concert with the 
spreading protrusion (Melton et al., 2007). Cell migration studies indicated that PDGF 
stimulated migration, but it had no effect on cell proliferation but PDGF-induced migration 
was inhibited by inhibitors of MEK/ERK, PI3K/Akt, EGFR and Src pathways in osteoblastic 
cells (Kim et al., 2007). Inhibition of protein kinase C and ERK also attenuated PDGF-
stimulated mesangial cell migration (Harper et al., 2007). Cerutis et al. (2004) showed that 
LPA plus PDGF elicited complete wound filling in periodontal ligament fibroblasts (PDLFs).  
Furthermore, Banerjee et al. (2006) identified PDGF as a key regulator of vascular smooth 
muscle cells motility induced by breast cancer cells. The PI3K signaling, but not the ERK 
signaling was strongly involved in the PDGF-stimulated glioma cell motility in T98G and U87-
MG cells (Cattaneo et al., 2006). In vitro, PDGF-BB expression activates cell motility of 
isolated lymphatic endothelial cells, whereas in vivo, in murine fibrosarcoma cells PDGF 
induces tumor lymphangiogenesis, leading to enhanced metastasis in lymph nodes (Cao et 
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1.7 Aims of the thesis 
 
Tenascin-C inhibits cell spreading on fibronectin by blocking the integrin α5β1 co-receptor 
syndecan-4, which prevents focal adhesion and actin stress fiber formation (Huang et al., 
2001; Orend, 2003). Studies by Ruiz et al. (2004), showed that the expression profile of 
glioma cells is profoundly altered upon growth on a fibronectin/tenascin-C substratum in 
comparison to fibronectin alone. This involved downregulation of actin stabilizing TM1 and 
up-regulation od EDNRA amongst many other molecules. Here, it should be addressed how 
tenascin-C prevents the formation of actin stress fibers and focal adhesions, two important 
components involved in cell spreading, in more detail. In particular, the mechanism of how 
inactivation of syndecan-4 by tenascin-C causes cell rounding on a fibronectin/tenascin-C 
substratum should be determined at the molecular level. Moreover, cytoplasmic signaling 
that leads to reduced expression of TM1 and inactivation of FAK should be examined in 
detail and it should be determined whether TM1 is a critical component of tenascin-C-
induced cell rounding. In addition, it should be analyzed how tenascin-C affects cell 
migration. Cells in tissues do encounter signals from the ECM together with signals from 
growth factors. As an example, in the tenascin-C enriched neuronal stem cell nice, tenascin-
C and PDGF receptor signaling is important for maintenance of the stem cell phenotype. 
Therefore, it should be determined how signaling from growth factors such as PDGF, LPA, 
endothelin and EGF affects cell adhesion and migration of cells on a fibronectin/tenascin-C 
substratum.  
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2.1 Part A : Endothelin receptor type B counteracts tenascin-C-induced 
endothelin receptor type A-dependent focal adhesion and actin stress fiber 
disorganization (publication) 
 


































Tenascin-C, an extracellular matrix molecule of the tumor specific microenvironment, 
counteracts the tumor cell proliferation-suppressing effect of fibronectin by blocking 
the integrin α5β1/syndecan-4 complex. This causes cell rounding and stimulates 
tumor cell proliferation. Tenascin-C also stimulates endothelin receptor type A 
(EDNRA) expression. Here, we investigated whether signaling through endothelin 
receptors affects tenascin-C-induced cell rounding. We observed, that endothelin 
receptor type B (EDNRB) activation inhibited cell rounding by tenascin-C and 
induced spreading by restoring expression and function of FAK, paxillin, RhoA and 
tropomyosin-1 (TM1) via activation of EGFR, PLC, JNK and the PI3K pathway. In 
contrast to EDNRB, signaling through EDNRA induced cell rounding which correlated 
with FAK inhibition and TM1 and RhoA protein destabilization in the presence of 
tenascin-C. This occurred in a MEKdependent manner. Thus, tumorigenesis might 
be enhanced by tenascin-C involving EDNRA signaling. Inhibition of tenascin-C in 
combination with blocking both endothelin receptors could present a strategy for 



























Cancer is a product of the tumor-host microenvironment, where mutual stimulation of 
tumor and stromal cells induce tumor formation and progression into malignant 
metastasizing cancers. The adhesion modulatory extracellular matrix (ECM) 
molecule tenascin-C is one factor in the tumor-specific microenvironment that is 
highly expressed in most solid tumors. Tenascin-C actions promote malignant 
transformation, uncontrolled proliferation, metastasis, angiogenesis and escape from 
tumor immunosurveillance. Tenascin-C acts very early during malignant 
transformation as well as throughout tumor progression through distinct effects on 
various cell types within a tumor (1). We and others have previously shown that 
tenascin-C inhibits the tumorigenesis-suppressing activity of integrin α5β1-mediated 
cell adhesion to fibronectin by blocking syndecan-4 (2, 3) and downstream RhoA (4) 
and FAK (2, 5, 6) activation. This in turn triggers tumor cell proliferation, presumably 
by overriding the G0 and G1/S cell cycle checkpoints (7). Moreover, tenascin-C can 
activate a variety of oncogenic signaling pathways such as EGFR (8, 9), ERK/MAP 
kinase and Wnt and can downregulate the tumor suppressor-like molecule 
tropomyosin-1 (TM1) (10). 
 
Endothelins (ET1-3) and their G protein-coupled receptors EDNR subtypes A and B 
were originally found to be involved in the regulation of blood pressure (11). 
Endothelin receptor signaling plays an important role during embryonic development, 
and in physiological processes such as neurotransmission, renal function and 
regulation of cell proliferation (12). EDNRB signaling has a promigratory and 
proliferative effect on microvascular endothelial cells (13). Signaling through EDNRA 
also stimulated angiogenesis in particular by induction of vascular endothelial growth 
factor (14, 15). ET1 activates phospholipase-C β, thus increasing intracellular 
calcium ion levels and activation of PKC. It also activates PI3K, JNK, ERK/MAP 
kinase and EGF receptor (EGFR) signaling. Moreover, ET1-induced signaling leads 
to activation of FAK and paxillin (16). Since signaling by EDNRA and EDNRB plays 
an important role in endothelial cell proliferation and survival, blocking these 
receptors provides a promising approach in clinical treatment of systemic pulmonary 
hypertension and chronic heart failure (17). Inhibition of endothelin receptor signaling 
may also be useful in cancer therapy, since inhibition of EDNRB with a selective  
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culture and in the nude mouse (18). In advanced prostate cancer, treatment with an  
EDNRA-selective inhibitor (ABT-627) delayed disease progression in patients with 
hormone-refractory prostate cancer (19).  
 
We showed that tenascin-C induces expression of EDNRA. This was accompanied 
by enhanced phosphorylation of ERK1/2 and induction of c-Fos (10), all downstream 
targets of EDNRA. Here, we investigated the possibility that EDNRA signaling 
contributes to the tenascin-C-induced cell phenotype. We show, that EDNRA 
signaling induced cell rounding in the presence of tenascin-C. This occurred by 
blocking FAK and paxillin activation, and inhibiting RhoA and TM1 protein stability in 
a MEK-dependent manner. In contrast to EDNRA, signaling by EDNRB counteracted 
cell rounding by tenascin-C and stimulated cell spreading on a fibronectin/tenascin-C 
(FN/TN-C) substratum in an EGFR-, PLC-, JNK- and PI3Kdependent, but MEK-
independent manner. In the absence of syndecan-4 activation, EDNRB signaling 
restored focal adhesion assembly by activating FAK and paxillin and, reorganized the 
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Material and Methods 
 
Construction and purification of his-tagged human tenascin-C 
The cDNA encoding human tenascin-C (HxBL.pBS) encompassing all alternative 
fibronectin type III repeats (20) was subcloned into the pCEP-Pu vector (21). A C-
terminal his-tag (6 additional his residues) was introduced by PCR with primer PhTN-
C R-2 (CGGGATCCTAATGATGATGATGATGATGATGTGCCCGTTTGCGCCT). A 
3-piece ligation of NotI/NdeI, a NdeI/6his -BamHI and a NotI/BamHI vector fragments 
gave rise to pCEP-huTNC-his. The construct was confirmed by restriction enzyme 
analysis, PCR and partial sequencing. After transfection of pCEP-huTNC-his into 
HEK293-EBNA1 cells (ATCC, CRL-10852), human tenascin-C expression and 
secretion were determined by immunoblotting with the monoclonal antibody B28.13 
(22). For large-scale production of recombinant human tenascin-C, 293:pCEP-
huTNC-his cells were grown to confluency in the presence of 2.5 µg/ml puromycin 
(Sigma, Bucks, Switzerland) in DMEM and 10% FCS. For collection of conditioned 
medium, cells were washed with PBS prior to growth in serum-free DMEM without 
puromycin for 2 days. Cells were recovered in DMEM supplemented with 10% FCS 
and 2.5 µg/ml puromycin for 1 day before transfer to serum-free medium. This cycle 
was repeated up to 8-times with no reduction in yield during prolonged culture.  
 
Proteins from conditioned medium were ammonium sulfate precipitated and dialyzed 
against PBS/0.01%Tween-20 prior to chromatography on a gelatine-agarose column 
(Sigma, Bucks, Switzerland, G5384). The eluate was passed over a nickel column 
(Invitrogen, Carlsbad, CA USA, Pro Bond Resin no. R801-01) and bound tenascin-C 
was eluted with 300 mM imidazol (Sigma, Bucks, Switzerland), 250 mM Na 
phosphate pH 7.4, 450 mM NaCl, 0.01% Tween-20 and dialyzed against PBS/0.01% 
Tween-20. The purity and absence of contamination by fibronectin was determined 
by Gelcode staining and immunoblotting. The biological activity of recombinant 
human tenascin-C was compared to the chicken tenascin-C used previously (2). In 
cell adhesion assays, T98G cells were plated for different times onto pure tenascin-
C, fibronectin or mixed fibronectin and fibronectin/FNIII13 substrata containing 
human or chicken tenascin-C. As with chicken tenascin-C (2), cells did not spread on 
FN/TN-C unless syndecan-4 was activated with FNIII13. To test whether addition of 
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fibrinogen globe, heparin binding of chicken and human tenascin-C were compared 
by ELISA. No differences were detected (data not shown). 
 
Cell plating, inhibitor studies, preparation of cell lysates 
Human T98G glioblastoma, J82 urinary bladder carcinoma and MDA-MB435 breast 
carcinoma cells (American Type Culture Collection) were grown in DMEM 
supplemented with antibiotics and 10% FCS (Sigma, Bucks, Switzerland). Cells were 
transferred into DMEM, 10% FCS 24 h before the experiment and serum-starved for 
18 h. Cells were trypsinized and replated after inhibition of trypsin with 100 ng/ml 
Trypsin inhibitor (Sigma, Bucks, Switzerland) in serum-free DMEM onto 10-cm2 
dishes (Falcon Becton Dickinson) coated with equimolar amounts of fibronectin and 
tenascin-C (1µg/cm2). Finally, 1% heat-inactivated BSA (Serva, Heidelberg, 
Germany) was used to block the uncoated surface prior to UV-sterilization for 15 min 
in a sterile bench. Since the inhibitors were dissolved in DMSO and DMSO interfered 
with cell spreading on fibronectin, cells were plated on the different substrata in 
serum-free medium 1h or 12h prior to incubation with 100 ng/ml EGF, 20 nM ET1, 20 
nM ET3, conditioned medium (taken from 48h serum-free cultures of  T98G cells), or 
inhibitor PKI166 (2 µM, Novartis, Basel, Switzerland), UO126 (25 µM, Calbiochem 
Germany, Darmstadt), wortmannin (20 µM), SP600125 (20 mM), U73122 (20 nM), 
BQ123 (100 nM) and BQ788 (100 nM) (Sigma, Bucks, Switzerland) for 4h followed 
by lysis in sample buffer (250 mM Tris-HCl pH 7,0, 10% SDS, 50 % glycerol, 






Equal amounts of protein were separated in 8% self-made or 4-12% precast Bis-Tris-
glycine gels (Invitrogen, Novex), transferred onto PVDF nylon membrane (Millipore 
Immobilon-P, Bedford, USA) and stained with 0.2% Ponceau-S (Sigma, Bucks, 
Switzerland) in 7.5% TCA for confirmation of equal protein loading prior to blocking 
the membrane in 10% horse serum (or 1% BSA), TBS, 1% Tween-20. For 
immunoblotting, the following mouse monoclonal antibodies against TM1-3 (TM311, 
Sigma, Bucks, Switzerland, 1:1000), vinculin (hVIN-1, Sigma, Bucks, Switzerland, 
1:1000), α-tubulin (Ab-1, Oncogene, Dietikon Switzerland, 1:5000), RhoA (26C4, 
Santa Cruz Biotechnology Inc., Heidelberg, Germany, 1:1000), P-ERK1/2 (Cell 
Signaling, Allschwil, Switzerland, 1:1000), FAK and phospho-Y397-FAK (BD 
Biosciences, Allschwil, Switzerland, 1:1000), rabbit polyclonal antibodies, paxillin and  
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phospho-Y118-paxillin (Abcam, Cambridge, UK, 1:1000), and ERK1/2 (Cell 
Signaling, Allschwil, Switzerland, 1:1000), phospho-S910-FAK (Biosource, Lucerne, 
Switzerland, 1:1000) and secondary HRP-coupled antibodies (Amersham, UK) were 
used. Binding of antibodies was detected with ECL-plus (Amersham, UK). 
 
Real-time reverse transcription PCR 
Total RNA was isolated from three independent plates using the RNeasy Mini Kit 
(Qiagen, Basel, Switzerland) and RNAse-free DNAse set (Qiagen, Basel, 
Switzerland) following the manufacturer’s instructions. From 0,5 –1 µg of total RNA 
single strand cDNA was generated by using the SuperScript III First-Strand 
Synthesis Super Mix (Invitrogen, Carlsbad, CA, USA) with random hexamers. 
Expression of the respective gene was detected by quantitative RT–PCR on an ABI 
Prism 7000 TaqMan using SYBR green PCR MasterMix (Applied Biosystems, 
Warrington, Cheshire, UK) with the following primers (5’ to 3’): GAPDH, 
ATCTTCTTTTGCGTCGCCAG (forward) and AATCCGTTGACTCCGACCTTC 
(reverse), tenascin-C, TGCCCATATCTCAGGGCTAC (forward) and 
GATGCCATCCAGGAAACTGT (reverse), EDNRA, 
GCCATATTTTAGGACAGGTAAAATAACA (forward) and 
AACACACAAAAGGGCAGTACTTCTT (reverse) (10), EDNRB, 
TCACCTAAAGCAGAGACGGGAA (forward) and AGGACCAGGCAAAAGACGG 
(reverse), αTM (TPM1), GCACCGAAGATGAACTGGACAA (forward) and reverse 
CATCGGTGGCCTTTTTCTCTG (reverse), βTM (TPM2), 
CCAACAACTTGAAATCCCTGG (forward) and CTTTGGTGGAATACTTGTCCGC 
(reverse) and RhoA, GCAGGTAGAGTTGGCTTTATGG (forward) and 
CTTGTGTGCTCATCATTCCGA (reverse) (23). Primers were designed with the ABI 
Primer Express software (Applied Biosystems, Warrington, Cheshire, UK). Relative 
expression of the respective gene was determined after normalization to GAPDH and 

















Cells were serum-starved prior to plating on fibronectin and FN/TN-C for the 
indicated time points in serum-free medium plus ET1 or ET3. Cells were fixed in 4% 
PFA and stained with the indicated primary and secondary FITC-labeled antibodies 
or with TRITC-labeled phalloidin (Sigma, Bucks, Switzerland). Images were captured 
using a NIKON Diaphot300 (NIKON Video Microscope with Openlab program,  
 
Coventry, UK) with 40x and 100x objectives for immunofluorescence and a Leica 
LEITZ DMIL microscope (Wetzlar, Germany) with a 10x objective for phase-contrast. 
 
Tissue Micro Arrays (TMA) and Immunohistochemistry 
TMAs with 190 glioblastoma (GBM), and 158 gliomas WHO grade I-III have been 
constructed from archived paraffin blocs as described (24). Expression of 
tropomyosin and tenascin-C in gliomas grade I, II and IV was determined by 
immunohistochemistry with antibody TM311 (dilution 1:3`500) and B28.13 (22), 
respectively as described before (10). The staining was scored semi-quantitatively in 



























Kinetics of EDNRA induction by tenascin-C 
We previously described that a tenascin-C containing fibronectin substratum 
triggered EDNRA expression in T98G cells 12h after contact with the substratum, 
both at RNA and protein level (10). Here, we investigated the kinetics of EDNRA 
induction by tenascin-C with real time RT-PCR. EDNRA RNA levels did not vary 
between cells plated on fibronectin or FN/TN-C at 1h and 3h (Fig. 1A). However, a 
slight and 2.7-fold increase was observed after 5h and 19h, respectively in cells 
plated on FN/TN-C. We also determined expression of EDNRB and found that in 
contrast to EDNRA, RNA levels of EDNRB were low and did not change at any of the 
time points mentioned above (data not shown). Thus, in contrast to EDNRB, 
expression of EDNRA is strongly induced by tenascin-C at RNA and protein level. 
 
 
             
 
Fig. 1 Kinetics of EDNRA expression and restoration of cell 
adhesion by ET1 on FN/TN-C 
(A) Expression of EDNRA was determined by real time-RT-PCR in 
T98G cells upon plating on fibronectin and FN/TN-C and after RNA 
preparation at the indicated time points. Expression of EDNRA on 
FN/TN-C is expressed as fold-difference in comparison to fibronectin 
alone. GAPDH expression was used for normalization. T98G cells 
were plated for 4h on fibronectin, and on FN/TN-C in the presence and 
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ET1 signaling restores cell adhesion on a fibronectin/tenascin-C substratum 
To examine whether EDNR signaling affects tenascin-C-induced cell rounding, we 
determined cell spreading of T98G cells on fibronectin in the presence and absence 
of tenascin-C, upon stimulation with the EDNR ligand endothelin-1 (ET1) in serum-
free medium. As previously observed, we confirmed that cells did not spread on 
FN/TN-C. But, stimulation with ET1 restored cell spreading on the FN/TN-C 
substratum (Fig. 1B). This was accompanied by actin stress fiber and focal adhesion 
formation 1h, 4h and 12h after plating of the cells (Fig. 1C, Supplemental Fig. 1). 
 













 T98G cells were plated for 4h on fibronectin, and on FN/TN-C in the presence and 
absence of ET1 before documentation of cell adhesion (B). Control: serum-free medium. 53









T98G cells were plated for 4h on fibronectin, and on FN/TN-C in the presence and absence 
of ET1 before documentation of  immunofluorescent staining for polymerized actin (arrow) 
with TRITC-phalloidin and for focal adhesions (arrow) with an anti-vinculin antibody (C). 




To determine how ET1 inhibited tenascin-C-induced cell rounding, the expression 
and function of tenascin-C target molecules was assayed. T98G cells were grown for 
4h on fibronectin or FN/TN-C in the presence or absence of ET1. Cell extracts were 
then analyzed by immunoblotting for FAK, active FAK (PY397-FAK), RhoA and TM1. 
Autophosphorylation of FAK at Y397, and expression of RhoA and TM1 were largely 
reduced in serum-free medium in the presence of tenascin-C. However, upon 
stimulation with ET-1, expression of P-Y397FAK, RhoA and TM1 were restored to 
levels observed on fibronectin alone. On fibronectin, ET1 also accelerated spreading 
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T98G cells were plated for 4h on fibronectin, and on 
FN/TN-C in the presence and absence of ET1 before  lysis 







ET1 inhibits tenascin-C signaling through activation of EDNRB 
T98G cells express two ET1 receptors, EDNRA (Fig. 1A) and EDNRB (25). To 
examine EDNR-specific effects we analyzed cell adhesion on FN/TN-C in the 
presence of specific inhibitors for EDNRA (BQ123) and EDNRB (BQ788) upon 
stimulation with ET1. T98G cells were plated for 1h or 12h on fibronectin or FN/TN-C 
before addition of ET1 and the respective EDNR inhibitor. Cells were then analyzed 
for adhesion followed by lysis and immunoblotting. As shown in figure 2A, inhibition 
of EDNRB with BQ788 caused cell rounding, thus blocking ET1-induced cell 
spreading on FN/TN-C 5h (data not shown) and 16h after plating. Inhibition of 
EDNRB by BQ788 also blocked restoration of autophosphorylation of FAK and 
reexpression of RhoA and TM1 on FN/TN-C at 5h and 16h (Fig. 2B). In contrast, the 
EDNRA specific inhibitor BQ123 did not block restoration of cell spreading by ET-1. 
Inhibition of EDNRA through BQ123 did also not affect FAK phosphorylation and 
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Fig. 2 EDNRB activation inhibits cell rounding on FN/TN-C
T98G cells were plated on fibronectin (not shown) and FN/TN-C in serum-free medium for 1h 
(B, C) and 12h (A, B) before addition of ET1 in the absence and presence of the EDNRA and 
EDNRB inhibitors BQ123 and BQ788, respectively for another 4h. (A) Documentation of cell 
adhesion. (B, C) immunoblotting for the indicated molecules.  
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To confirm that signaling specifically through EDNRB inhibits tenascin-C-induced cell 
rounding, T98G cells were stimulated with ET3, an EDNRB ligand that has several 
fold higher affinity for EDNRB than for EDNRA (11). Subsequently, cell adhesion was 
determined prior to lysis and immunoblotting. ET3 also stimulated cell spreading, and 
formation of focal adhesions and actin stress fibers in the presence of tenascin-C 
(Fig. 1C). Moreover, spreading was EDNRB-dependent since it was blocked with 
BQ788 (Supplemental Fig. 2A). As for ET1, activation of EDNRB with ET3 restored 
TM1 and RhoA expression and autophosphorylation of FAK in the presence of 
tenascin-C (Supplemental Fig. 2B). 
 
ET1 restores cell spreading by mediating focal adhesion assembly 
EDNRB signaling leads to cell-matrix adhesion and appearance of numerous focal 
contacts even in the presence of tenascin-C (Fig. 1C). To investigate in more detail 
how EDNRB signaling could enhance focal adhesion assembly, we examined 
whether FAK was phosphorylated at S910, a site that is involved in binding of FAK to 
paxillin (26, 27). Whereas P-S910-FAK levels were low on FN/TN-C, phosphorylation 
of FAK at S910 returned to levels as on fibronectin upon stimulation with ET1 (Fig. 
2C). Next, we examined whether FAK was functional in phosphorylating paxillin at 
Y118, one of its cognate phosphorylation sites (28), after stimulation with ET1. In 
cells plated on FN/TN-C in the absence of ET1, phosphorylation at Y118 in paxillin 
was abolished (Fig. 2C). In contrast, cells plated on FN/TN-C in the presence of ET1 
showed high levels of phosphorylated paxillin (Fig. 2C). Altogether, these data show 
that ET1 signaling through EDNRB restored FAK and paxillin activities in the 




















   
T98G cells were plated for 4h on fibronectin, 
and on FN/TN-C in the presence and 
absence of ET1 before lysis and 
immunoblotting for FAK, RhoA, TM1 and 




Activation of EDNRB induces cell spreading in an EGFR-, PLC-, PI3K- and JNK-
dependent manner 
We next investigated by which pathway EDNRB inhibits tenascin-C-mediated cell 
rounding. Since EDNR signaling activates EGFR, we addressed whether EDNRB-
induced cell spreading on FN/TN-C involves EGFR function. Cells were plated on 
FN/TN-C for 5h together with ET1 and the inhibitor PKI166, which prevents 
autophosphorylation of EGFR (29). Cell adhesion was documented prior to lysis and 
immunoblotting. Inhibition of EGFR by PKI166 completely blocked cell spreading by 





















           
 
Fig. 3 EDNRB activation induces cell spreading dependent on EGFR, 
PLC, PI3K and JNK 
T98G cells were plated on fibronectin or FN/TN-C for 1h in serum-free 
medium before addition of ET1 and DMSO in the presence or absence of the 
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Moreover, as shown in Figure 3B, PKI166 efficiently blocked ERK1/2 
phosphorylation and ET1-induced TM1 and RhoA expression in the presence of 
tenascin-C. However, ET1-induced autophosphorylation of FAK was not affected by 
PKI166 (Fig. 3B). Thus, ET1 restores TM1 and RhoA protein expression in the 
presence of tenascin-C through activation of EGFR. In contrast, activation of FAK by 
EDNRB is independent of EGFR signaling, but FAK activation alone is not sufficient 
to mediate cell spreading. 
 
         
T98G cells were plated on fibronectin or 
FN/TN-C for 1h in serum-free medium 
before addition of ET1 and DMSO in the 
presence or absence of the respective 
inhibitor. (B) immunoblotting. Control see 
Fig. 2. 
 
ET1-treated cells were allowed to adhere on FN/TN-C in the presence of inhibitors 
for PLC, MEK, PI3K and JNK. Inhibition of PLC with U73122 blocked ET1-induced 
cell spreading on FN/TN-C (Fig. 3A), which correlated with low levels of P-FAK, TM1 
and RhoA (Fig. 3C). Examining MEK and PI3K downstream of EGFR and PLC, 
revealed that the MEK inhibitor UO126 did not affect ET1-induced cell spreading on 
the tenascin-C substratum. This was in contrast to the PI3K inhibitor wortmannin 
which diminished cell spreading (Fig. 3A). Cell rounding by wortmannin correlated 
with largely reduced RhoA and TM1 levels and lack of FAK autophosphorylation in 
the presence of ET1 on FN/TN-C (Fig. 3D). These data suggest that EDNRB-
induced cell spreading on FN/TN-C depends on EGFR, PLC and PI3K, but does not 







                                             Results: EDNRA supports and EDNRB inhibits cell rounding by tenascin-C 
 
 
                       
 
T98G cells were plated on fibronectin or FN/TN-C for 1h 
in serum-free medium before addition of ET1 and DMSO 
in the presence or absence of the respective inhibitors.  





Next, we examined whether c-Jun aminoterminal kinase JNK, a downstream effector 
of EDNR and EGFR signaling, is involved in cell spreading on FN/TN-C upon 
activation of EDNRB. Inhibition of JNK with SP600125 not only prevented ET1-
induced cell spreading (Fig. 3A), but also blocked FAK autophosphorylation and 
TM1 reexpression in the presence of tenascin-C, which was in contrast to RhoA, the 
expression of which was not altered upon JNK inhibition (Fig. 3E). Altogether, these 
data suggest that EDNRB activation counteracts tenascin-C-induced cell rounding 
through EGFR and downstream PLC, JNK and PI3K, and that all three molecules 
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 T98G cells were plated on fibronectin or FN/TN-C for 1h in serum-
free medium before addition of ET1 and DMSO in the presence or 
absence of the respective inhibitors.  





Inhibition of EDNRA induces cell spreading in the presence of tenascin-C 
Since plating cells on a tenascin-C-containing substratum leads to increased 
expression of EDNRA, we asked whether EDNRA signaling could induce cell 
rounding in cells plated on FN/TN-C. We determined cell adhesion in the presence of 
both EDNR inhibitors at a time point when EDNRA expression was induced by 
tenascin-C. T98G cells were plated in serum free medium for 12h before addition of 
ET1 and the respective inhibitor for an additional 30 minutes (Supplemental Fig. 3) 
or 4h (Fig. 4). We observed that whereas cells were round 12h after plating on 
FN/TN-C, they spread with ET1 in the presence of both inhibitors (Fig. 4A). Since 
inhibition of EDNRB by BQ788 prevented cell spreading (Fig. 2A), restoration of cell 
spreading under these conditions was due to inhibition of EDNRA. Already 30 
minutes upon addition of exogenous ET1, T98G cells were spread on FN/TN-C 
(Supplemental Fig. 3A). Thus, inhibition of EDNRA rapidly overcomes cell rounding 
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added ET1 also induced cell spreading suggesting that EDNRA is active in the 
absence of exogenously provided ET1 (Fig. 4A, Supplemental Fig. 3A). EDNRA is 
presumably activated in T98G cells on FN/TN-C by secreted endothelins ((25), M. 
Kammerer and G. Orend, data not shown). To proof this possibility, cells on FN/TN-C  
were stimulated with conditioned medium derived from 48h serumfree cultures of 
T98G cells. Cells remained round on the FN/TN-C substratum with conditioned 
medium, but spread under these conditions upon inhibition of EDNRA with BQ123 
(Fig. 4A).  
 
 




Fig. 4 EDNRA-induced cell rounding on FN/TN-C is MEK-dependent
T98G cells were plated for 12h (A) on fibronectin or FN/TN-C in serum-free medium before 
addition of conditioned medium (CM) from 48h serum-free cultures, ET1, DMSO, BQ123, BQ788 
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Immunoblotting revealed that FAK autophosphorylation and expression of RhoA and 
TM1 were restored at 30 minutes (Supplemental Fig. 3B) and 4h (Fig. 4B) upon 
blocking of EDNRA. In addition, inhibition of both endothelin receptors enhanced 
ERK1/2 phosphorylation on FN/TN-C which was in contrast to the control with very 
low P-ERK1/2 levels. To examine whether activation of EDNRA by tenascin-C 
causes rounding in MDA-MB435 breast carcinoma and J82 urinary bladder 
carcinoma cells that express EDNRA as determined by real time RT-PCR (M. 
Kammerer and G. Orend, unpublished), we determined adhesion of these cells on 
fibronectin and FN/TN-C upon treatment with BQ123. As for T98G, these cells did  
not spread on FN/TN-C and, inhibition of EDNRA with BQ123 restored cell spreading 
on FN/TN-C (Supplemental Fig. 4A). Thus, activation of EDNRA mediates rounding 
of all three cell lines by tenascin-C. 
  
 
                  
 
T98G cells were plated for 12h (B)  on fibronectin or FN/TN-C 
in serum-free medium before immunoblotting for the 
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EDNRA-specific cell rounding by tenascin-C is MEK-dependent 
We wanted to know whether the MAP kinase pathway, that blocks expression of TM1 
(30, 31), is involved in EDNRA-stimulated inhibition of TM1 expression by tenascin-
C. Therefore, cells plated onto FN/TN-C were stimulated with ET1 in the presence of 
the EDNRB inhibitor BQ788, which allows to determine signaling in response to 
EDNRA activation. Inhibition of the MEK pathway by UO126 restored cell spreading 
in combination with BQ788 (Fig. 4C). Thus, MEK is downstream of EDNRA. UO126 
also normalized TM1 and RhoA expression and FAK autophosphorylation on FN/TN-
C to levels as on fibronectin upon treatment with ET1 and BQ788 (Fig. 4D). Thus, 
activation of MEK through EDNRA contributes to tenascin-C-induced cell rounding 
on fibronectin by blocking FAK activation and RhoA and TM1 expression. 
 
 
      
 T98G cells were plated for 1h (C) on fibronectin or FN/TN-C in serum-free 
medium before addition of ET1, DMSO, BQ788 and UO126. (C) documentation 
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T98G cells were plated for 1h (D), on fibronectin or FN/TN-C in serum-free 
medium before addition of ET1, DMSO, BQ788 and UO126. (D) immunoblotting 






Regulation of TM1 and RhoA RNA and protein levels on FN/TN-C 
To determine whether tenascin-C affects RNA levels of αTM (coding for TM2 and 3), 
βTM (coding for TM1) and RhoA, a real time RT-PCR experiment was performed on 
RNA prepared from cells that were grown in the presence or absence of tenascin-C 
for different time points. In T98G cells RNA levels of αTM started to drop at 5h and 
remained about 40-50% below those on fibronectin after 19h on FN/TN-C (Fig. 5A). 
A similar observation was made for J82 cells (Supplemental Fig. 5B). This was in 
contrast to earlier time points (1h and 3h) where no substratum-specific differences 
in αTM expression were observed in T98G cells (Fig. 5A). Similarly, βTM and RhoA 
RNA levels were not downregulated on FN/TN-C in comparison to fibronectin at any 
time point (Fig. 5B, C). These results show that RNA levels of αTM, βTM and RhoA 
are not reduced in the presence of tenascin-C at early time points. 
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Fig. 5 Regulation of αTM, TM1 and RhoA RNA and 
protein levels on FN/TN-C 
T98G cells were plated on fibronectin or FN/TN-C for the 
indicated time points (A - C)  in serum-free medium (A – 





















Next, we examined TM1 and RhoA protein stability on FN/TN-C and observed that 
TM1 and RhoA protein levels were restored on FN/TN-C to levels as observed on 
fibronectin upon treatment with the proteasome inhibitor ALLN (Fig. 5D). In contrast, 
phosphorylation of FAK was not restored with ALLN and this observation correlated 
with the inability of cells to spread on FN/TN-C under these conditions (Table 1). 
Since αTM levels dropped significantly after 19h and, BQ123 restored TM1 
expression on FN/TNC, we examined whether EDNRA signaling contributed to 
reduced αTM RNA levels in T98G and J82 cells. But inhibition of EDNRA by BQ123 
only slightly increased αTM levels on FN/TN-C in both cell lines (Supplemental Fig. 
5). In summary, our data suggest, that enhanced proteolysis of TM1 and RhoA is the 
major mechanism by which EDNRA negatively regulates expression of RhoA and 
TM1 on FN/TN-C. 
 
 
                
 
T98G cells were plated on fibronectin or FN/TN-C for 5h (D) 
























Cell spreading and downstream events presented in this study are summarized. The presence (1) 
or absence (0) of cell spreading (4th column), on FN/TN-C upon stimulation with ET1 or ET3 is 
indicated as deduced from immunofluorescent staining with TRITC-phalloidin and an anti-vinculin 
antibody or by phase contrast microscopy. Data are shown on the effect of the inhibitors BQ788 
(EDNRB), BQ123 (EDNRA), PKI166 (EGFR), U73122 (PLCβ/γ), Wm (PI3K), UO126 (MEK) and 
SP600125 (JNK). The absence (0) or presence (1) of phosphorylated FAK (P-Y397-FAK), and 
RhoA and TM1 protein on FN/TN-C is depicted. Relative activity of EDNRA and EDNRB is shown in 
the second column. 
 
 
Expression of tenascin-C and EDNRA in cancer tissue 
Next, we compared gene expression levels of tenascin-C and EDNRA in 80 GBM 
and four non-tumoral brain tissue (GeneChips U133 Plus, Affymetrix; manuscript in 
preparation) by SPIN analysis (sorting points into neighborhoods) (32) and by 
systematically evaluating gene expression changes using the ONCOMINE 3.1 
platform (33). Tenascin-C and EDNRA mRNA expression revealed some correlation 
in GBM (pearson correlation 0.47) and in astrocytoma with high expression in 
gliomas and low expression in non-tumoral brain tissue (Fig. 6A, Supplemental 
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EDNRA regulation in GBM. Moreover, the majority of GBM exhibited also a high 
expression of EDNRB (Fig. 6A, Supplemental Table 1) with EDNRA and EDNRB 
showing a negative correlation (pearson correlation – 0.25) (Fig. 6A). On protein 
level, as determined by immunohistochemistry on TMAs, tropomyosin expression 
displayed different staining patterns. Tumor tissue was homogenously positive or 
negative for TM1-3, while staining of aberrant blood vessels was prominent in most 
tumors (Fig. 6B). There was neither a correlation of TM1-3 protein expression with 
tumor grade (Fisher exact test, p=0.09) nor with tenascin-C protein expression 
(Fisher exact test, p=0.09) in GBM. These observations suggest that other factors 
than tenascin-C influence tropomyosin expression in gliomas under steady-state 
conditions in a cell type specific manner. 
 
 
             
 
 Fig. 6 Expression of tenascin-C, EDNR and tropomyosin in gliomas 
(A) Gene expression of tenascin-C and potential mediators as ordered by 
SPIN analysis for 80 GBM. The ordering of points is iteratively permutated in 
search of a linear ordering. Expression is represented in a colour scale (log2) 



















            
 
Fig. 6 Expression of tenascin-C, EDNR and tropomyosin in gliomas 
(B) Four representative examples of immunohistochemical staining for TM1-3 





Searching the Oncomine database for a potential linked expression of tenascin-C 
and EDNRA in other human cancers revealed a high tenascin-C expression and 
increased EDNRA expression in malignant pancreatic ductal carcinoma, seminoma, 
bladder carcinoma, breast carcinoma and in metastatic ovarian carcinoma 
(Supplemental Fig. 6, Supplemental Table 1). On the contrary, a lowered tenascin-
C expression in metastatic prostate and a subset of colon carcinoma correlated with 
reduced EDNRA expression. These observations are compatible with a potential 
regulation of EDNRA by tenascin-C in these cancers. EDNRB and αTM were also 
increased in astrocytoma, ovarian carcinoma, breast carcinoma, seminoma and 
pancreatic ductal carcinoma (Supplemental Table 1) which also matches with a 













    Fig. 7 Tenascin-C induces EDNRA signaling that is counteracted by EDNRB 
(A) Upon activation of integrin α5β1 and syndecan-4 by fibronectin, cells activate FAK and 
RhoA upstream of TM1 which leads to actin polymerization and filament stabilization and 




























 Fig. 7 Tenascin-C induces EDNRA signaling that is counteracted by EDNRB  
 
(B) Tenascin-C induces EDNRA expression and EDNRA-induced MEK-dependent signaling 
causes enhanced proteolysis of TM1 and RhoA. This leads to cell rounding on a FN/TN-C 
substratum. In contrast to EDNRA, signaling by EDNRB (induced by ET1 or ET3) restores FAK 
and paxillin phosphorylation and downstream stabilization of TM1 and RhoA and, subsequently 
leads to cell spreading on FN/TN-C. This involves EGFR, PLC, PI3K, JNK, and other not yet 
identified downstream signaling molecules. EDNRB signaling might activate EGFR indirectly, 
presumably due to enhanced maturation of pro-EGF (40). It is remarkable that EDNRB-induced 



























Previously, we and others showed that the function of FAK (2, 5), RhoA (4) and TM1 
(10) is compromised in cells grown on FN/TN-C. This occurred in a syndecan-4 
dependent manner since activation of syndecan-4 restored cell spreading and FAK 
activation in the presence of tenascin-C (2, 5) (Fig. 7A). Here we observed, that 
tenascin-C does not only interfere with RhoA activation (4), but also with RhoA 
protein stability. Moreover, we showed a complex repression of TM1 by tenascin-C. 
Although TM1 protein levels were reduced by tenascin-C, RNA levels were not 
lowered by tenascin-C at any time point up to 19h. In contrast, TM1 protein stability is 
largely reduced by tenascin-C, since inhibition of the proteasome with ALLN restored 
TM1 protein levels on FN/TN-C. After 19h, RNA levels of αTM coding for TM2 and 3, 
that are less expressed in T98G cells, significantly dropped. Reduced αTM levels 
might contribute to reduced TM1 expression, since TM1 forms heterodimers with 
TM2 and 3. 
Our results show that inhibition of FAK, RhoA and TM1 is responsible for cell 
rounding by tenascin-C. To override the cell spreading block by tenascin-C, the 
function of all three molecules FAK, RhoA and TM1 needs to be restored (Fig. 7B, 
Table 1). This can be accomplished by activation of EDNRB, which induces cell 
spreading on FN/TN-C presumably due to FAK and paxillin activation and RhoA and 
TM1 protein stabilization. EDNRB-induced cell spreading on FN/TN-C was specific 
since it could be blocked with BQ788, a specific inhibitor of EDNRB (18) that is used 
in treatment of pulmonary hypertension (17). Restoration of expression and function 
of FAK, RhoA and TM1 by EDNRB signaling involved EGFR, PLC, PI3K and JNK, 
since specific inhibitors for these enzymes blocked EDNRB-specific cell spreading 
and reexpression of the tenascin-C target molecules. 
 
We observed that activation of paxillin, an important component of integrin (28), 
syndecan-4 (34) and ET1 (11) signaling plays a key role in EDNRB-induced cell 
spreading on FN/TN-C, since EDNRB signaling induced phosphorylation of paxillin at 
Y118, one of its cognate phosphorylation sites for FAK (28) in the presence of 
tenascin-C. Whereas, phosphorylation of FAK at S910 and of paxillin at Y118 was 
absent or very low in the presence of tenascin-C in serum-free medium, EDNRB 
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phosphorylation of FAK at S910 is involved in restoration of cell spreading on FN/TN- 
C presumably by phosphorylating paxillin. Localization of paxillin into focal adhesions 
is dependent on syndecan-4, which involves binding of syndesmos to syndecan-4 
and paxillin (34). Tenascin-C impairs syndecan-4 activation by fibronectin (2), and 
prevents localization of paxillin into focal adhesions (5). Now, we showed that 
EDNRB activation restores focal adhesion formation on the FN/TN-C substratum. 
This suggests, that EDNRB signaling restores paxillin function on a FN/TN-C 
substratum through bypassing the requirement for syndecan-4 for the recruitment of 
paxillin into focal adhesions (Fig. 7B). 
 
Tenascin-C stimulated EDNRA expression (10). By using the clinically relevant 
EDNRA-specific inhibitor BQ123 (17) we observed that inhibition of EDNRA restored 
cell spreading, which suggests that signaling through EDNRA mediated cell rounding 
on FN/TN-C. Similar to T98G glioblastoma cells, activation of EDNRA in MDA-
MB435 breast carcinoma and J82 urinary bladder carcinoma cells also supported cell 
rounding by tenascin-C that could be blocked with BQ123. Whereas endogenously 
expressed ET1 activated EDNRA, exogenously added ET1 at a high concentration of 
20 nM also activated EDNRB. Thus, upon activation of both receptors, signaling by 
EDNRB dominated over signaling by EDNRA in T98G, and in MDA-MB435 and J82 
cells. Different affinities of EDNRA and EDNRB for the ligand, as has been reported 
by others (35), can explain our observation that activation of EDNRB as well as 
inhibition of EDNRA restored cell spreading on FN/TN-C. 
 
Since activation of EDNRA (our data) and MEK downregulates TM1 expression (30, 
31, 36), we examined whether EDNRA-associated cell rounding on FN/TN-C was 
dependent on MAP kinase signaling. Indeed, inhibition of MEK with UO126 blocked 
EDNRA-specific cell rounding on FN/TN-C and caused restoration of FAK 
phosphorylation and stabilization of RhoA and TM1. Our data link TM1 and RhoA 
protein instability to EDNRA (Table 1). 
 
Tenascin-C induced EDNRA expression later than 5h after plating, suggesting that 
EDNRA signaling is important for tenascin-C-induced cell rounding on fibronectin at 
later time points. This could present a mechanism to enhance or maintain tenascin-
C-induced cell rounding. Whether this involves syndecan-4 is unknown. A potential 
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our observation that ligation of syndecan-4 is sufficient to restore cell spreading on 
Fibronectin and to attenuate tumor cell proliferation in the presence of tenascin-C (2). 
Moreover, activation of EDNRA did not induce cell rounding in cells that were spread 
on fibronectin, where syndecan-4 is engaged as coreceptor in integrin signaling. We 
speculate that in situations where syndecan-4 is not working as coreceptor for 
integrin signaling, syndecan-4 might acquire other functions as e.g. promoting 
EDNRA signaling resulting in cell rounding in the presence of tenascin-C. 
 
Tenascin-C and endothelin receptors are instrumental in neural crest cell (NCC) 
migration during embryonic development, since NCC migration was blocked in 
chicken embryos that were treated with tenascin-C antisense morpholinos (37). The 
homozygous knock-outs of EDNRA and EDNRB are embryonic lethal (38) and 
EDNRA and EDNRB signaling is crucial in NCC migration (39). Our data provide a 
functional link between tenascin-C, EDNRA and NCC migration. Tenascin-C may 
promote NCC migration along tenascin-C-rich cues by stimulating EDNRA signaling. 
 
Our results suggest, that responses towards tenascin-C largely depend on the 
growth factor receptor status of a cell. EDNRA supports cell rounding by tenascin-C, 
through concomittant repression of RhoA and TM1. Our report is the first to link 
EDNRA with MEK signaling and cell rounding on a FN/TN-C substratum and 
enhanced proteolysis of RhoA and TM1. Moreover, similar expression of tenascin-C 
and EDNRA in 8 human cancers is compatible with tenascin-C playing a role in 
regulation of EDNRA in vivo. In contrast to EDNRA, we found that EDNRB blocks 
cell rounding by tenascin-C through activation of FAK and normalizing expression of 
RhoA and TM1. We linked EDNRB, EGFR, PLC, PI3K and JNK to cell spreading in 
the presence of tenascin-C. Moreover, EDNRB signaling appears to antagonize 
signaling through EDNRA. A potential interdependence of the two signaling 
pathways has been reported; inhibition of EDNRA with BQ123 significantly enhanced 
EDNRB-induced proliferation of endothelial cells (13). An increased EDNRB and 
αTM expression found in 5 human cancers supports the possibility that EDNRB 
signaling could be involved in αTM regulation in a steady-state situation. More 
detailed information is required to unravel potential interrelations between tenascin-












In summary, we presented a detailed mechanism by which tenascin-C causes cell 
rounding through EDNRA, and how cells modulate the anti-adhesive properties of 
tenascin-C through EDNRB and presumably other signaling. This is the first study to 
reveal that cell responses towards tenascin-C are modulated by growth factor 
signaling. More information is required about signaling pathways that support or 
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Supplemental Fig. 1 Kinetics of restored actin stress fiber and focal adhesion formation by 
ET1 
T98G cells were plated for the indicated time points on FN/TN-C in the absence and presence of 










                     
 
Supplemental Fig. 2 Inhibition of EDNRB blocks ET3-induced cell spreading on 
FN/TN-C 
T98G cells were plated on fibronectin and FN/TN-C in serum-free medium for 1h 
before addition of ET3 in the absence and presence of the EDNRB inhibitor BQ788 or 






















Supplemental Fig. 3 Rapid induction of cell spreading on FN/TN-C upon inhibition of 
EDNRA 
T98G cells were plated for 12h on FN/TN-C in serum-free medium before addition of ET1 
and the inhibitors BQ123 and BQ788 for 30 minutes. As control, cells were plated in serum-
free medium plus DMSO. (A) Documentation of cell adhesion, (B) immunoblotting for the 
indicated molecules. 




          
 
Supplemental Fig. 4 Induction of cell spreading on FN/TN-C in breast and urinary 
bladder carcinoma cells upon inhibition of EDNRA 
Human breast carcinoma MDA-MB435 and J82 urinary bladder carcinoma cells were 
plated on FN/TN-C in serum-free medium before addition of ET1, DMSO and BQ123 


















                       
 
Supplemental Fig. 5 Effect of EDNRA inhibition on αTM 
repression 
T98G (A) and J82 cells (B) were plated for 12h and 1h, respectively 
on fibronectin and FN/TN-C before addition of ET1, BQ123 or DMSO 































































Relative expression (0, equal; 1, increase and –1, decrease) of tenascin-C, EDNRA, EDNRB 
and αTM transcript(s) in tumor and normal tissues was obtained from meta-analysis of cancer 
gene microarray meta-analysis public database (http://www.oncomine.org). Statistical 
analysis of differences (p<0.05) was performed using ONCOMINE algorithms to account for 
the multiple comparisons among different studies, similar to a meta-analysis, as previously 
described (Rhodes et al., 2004, Neoplasia 6, 1).The number of samples is shown in brackets. 
(b) For real time RTPCR, breast cancer specimen (n=13) of grade 1 and grade 3 breast 
tumors were obtained from patients operated between 2002 and 2003 at the Department of 
Gynecology, University of Münster, Germany (Wülfing et al., 2005, Int J Oncol 26, 951). 
Tumor samples were snap frozen immediately after surgery and stored at –80° C until RNA 
extraction. Non-neoplastic breast tissue samples (n = 7) were obtained from patients 




























































 Supplemental Fig. 6 Expression of tenascin-C, EDNRA, EDNRB and αTM in human 
cancer tissue 
Expression of tenascin-C, EDNRA, EDNRB and αTM transcript(s) in tumor and normal 
tissues of astrocytoma (A) was obtained from meta-analysis of cancer gene microarray 
meta-analysis public database (http://www.oncomine.org). Statistical analysis of 
differences (p<0.05) was performed using ONCOMINE algorithms to account for the 
multiple comparisons among different studies, similar to a meta-analysis, as previously 








































Supplemental Fig. 6 Expression of tenascin-C, EDNRA, EDNRB and αTM in human 
cancer tissue 
Expression of tenascin-C, EDNRA, EDNRB and αTM transcript(s) in tumor and normal 
tissues of  seminoma (B) was obtained from meta-analysis of cancer gene microarray 
meta-analysis public database (http://www.oncomine.org). Statistical analysis of 
differences (p<0.05) was performed using ONCOMINE algorithms to account for the 
multiple comparisons among different studies, similar to a meta-analysis, as previously 









































Supplemental Fig. 6 Expression of tenascin-C, EDNRA, EDNRB and αTM in human 
cancer tissue 
Expression of tenascin-C, EDNRA, EDNRB and αTM transcript(s) in tumor and normal 
tissues of invasive bladder carcinoma (C) was obtained from meta-analysis of cancer 
gene microarray meta-analysis public database (http://www.oncomine.org). Statistical 
analysis of differences (p<0.05) was performed using ONCOMINE algorithms to account 
for the multiple comparisons among different studies, similar to a meta-analysis, as 
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2.2 Part B : Promotion of a motile phenotype by the microenvironmental 
factors tenascin-C and LPA/PDGF  
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Expression of tenascin-C, a prominent component of the tumor microenvironment 
and the neuronal stem cell niche, correlates with a poor survival prognosis for 
patients with gliomas and regulates oligodendrocyte progenitor maintenance, 
respectively. But the role of tenascin-C in these tissues and compartments is largely 
unknown at the mechanistic level. Here, we show that cooperative signaling by 
LPA/PDGF induces glioma cell spreading and migration on a mixed 
fibronectin/tenascin-C substratum. This effect depends on PI3K, ROCK and MEK, 
but is independent of syndecan-4, PLC and JNK. By using functional knock-down 
approaches, we identified paxillin and tropomyosin-1 as targets of tenascin-C 
downstream of syndecan-4, that are critical for LPA/PDGF-induced cell adhesion and 
migration under these conditions. Ectopic expression of paxillin and syndecan-4 
binding syndesmos also bypassed syndecan-4 requirement for cell spreading. In 
summary, the microenvironmental factors tenascin-C, LPA and PDGF stimulate cell 
spreading and migration, and thereby may contribute to glioma progression and 




























The microenvironment is instrumental for stem cell niche identity and cancer 
progression. Growth factors including EGF and PDGF regulate oligodendrocyte 
progenitor (OP) maintenance in the neuronal stem cell niche (fFrench-Constant; 
Goldman and Sim, 2005; Goldman, 2003). The extracellular matrix molecule 
tenascin-C is another component of this compartment. Tenascin-C is required for 
proper cell responses of OPs toward PDGF (Gibney and McDermott, 2007), which 
suggests a synergistic effect of tenascin-C and PDGF. Tenascin-C is also expressed 
in the stroma of most solid tumors, where its high expression correlates with tumor 
progression for some cancers including gliomas (Chiquet-Ehrismann and Chiquet, 
2003). Tenascin-C appears to play a role in tumor progression through stimulation of 
tumor cell proliferation, invasion, angiogenesis and suppression of the immune 
system (Orend and Chiquet-Ehrismann, 2003). But the underlying mechanisms are 
poorly understood. Tenascin-C competes with syndecan-4 binding to fibronectin, 
thus blocking cell adhesion to fibronectin. This translates into enhanced proliferation 
of glioma cells (Huang et al., 2001), presumably through activation of Wnt (Ruiz et 
al., 2004) and endothelin receptor type A (EDNRA) signaling (Lange et al., 2007). 
Tenascin-C promotes invasion through activation of HGF signaling (DeWever et al., 
2004). We showed that activation of EDNRA signaling by tenascin-C inhibits FAK 
and blocks actin stress fiber formation through downregulation of RhoA and 
tropomyosin-1 (TM1) (Lange et al., 2007).  
The proteoglycan syndecan-4 is a cofactor for integrin α5β1 in cell spreading on 
fibronectin (Huang et al., 2001). Syndesmos, an adaptor protein that binds both 
syndecan-4 and paxillin (Denhez et al., 2003), may provide a molecular bridge 
between α5β1 integrin and syndecan-4 in focal adhesions. Paxillin and FAK are 
other adaptor proteins that integrate signals from different membrane receptors 
including those from integrins and the PDGF receptor (Turner et al., 2005; Horwitz et 
al. 2005; Schlaepfer et al., 2004; Mitra et al., 2005).  
The small GTPase RhoA and its downstream targets RhoKinase (ROCK) and 
myosin light chain (MLC) are important molecules in actin polymerisation, cell 
contractility and migration. In addition, actin filaments are stabilised by tropomyosins. 







                                                 Results: Promotion of a motile phenotype by tenascin-C and LPA/PDGF 
 
 
Leder, 2001; Bhattacharya et al., 1990; Raval et al., 2003; Pawlak et al., 2004) and is 
repressed on a fibronectin/tenascin-C substratum (FN/TN) by a mechanism that 
involves reduced TM1 heterodimer stabilization due to reduced RNA levels of TM2 
and TM3 by tenascin-C.  
LPA and PDGF signaling is frequently deregulated in cancer and is highly elevated in 
gliomas. A high expression of both factors correlates with advanced cancers 
presumably by promoting survival, proliferation, migration and invasion (Stähle et al., 
2003; Gschwind et al., 2002; Banerjee et al., 2002; Cao et al., 2004). An enhanced 
migration is a prerequisite for invasion and metastasis, thus presumably promoting 
tumor progression. 
Here, we wanted to know how tenascin-C, LPA and PDGF affect adhesion and 
migration of glioma cells. We show that LPA/PDGF blocks cell rounding by tenascin-
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Materials and Methods 
 
Cell plating, inhibitor studies, preparation of cell lysates 
Human T98G glioblastoma and MEFs were grown in DMEM supplemented with 
antibiotics and 10% FCS (Sigma, Bucks, Switzerland). Cells were transferred into 
DMEM, 10% FCS 24 h before the experiment and serum-starved for 18 h. Cells were 
trypsinized and replated after inhibition of trypsin with 100 ng/ml trypsin inhibitor 
(Sigma, Bucks, Switzerland) in serum free DMEM onto dishes (Falcon Becton 
Dickinson) coated with equimolar amounts of fibronectin and tenascin-C (1µg/cm2). 
Recombinant his-tagged human tenascin-C, FNIII13 and serum-derived horse 
fibronectin was purified as described (Huang et al., 2001; Lange et al., 2007).  
Finally, 1% heat-inactivated BSA (Serva, Heidelberg, Germany) was used to block 
the uncoated surface prior to UV-sterilization for 15 minutes in a sterile bench. Since 
the inhibitors were dissolved in DMSO and DMSO interfered with cell spreading on 
fibronectin, cells were plated on the different substrata in serum free medium 1 h 
prior to incubation with 100 ng/ml EGF, 1µM LPA and 80 ng/ml PDGF-BB (Sigma, 
Switzerland), or inhibitor UO126 (25 µM, Calbiochem Germany, Darmstadt), 
Wortmannin (20 µM), SP600125 (20 mM) and U73122 (20 nM), respectively (Sigma, 
Bucks, Switzerland) for 4 h followed by lysis in sample buffer (250 mM Tris-HCl pH 
7,0, 10% SDS, 50 % glycerol, bromphenolblue, 100mM DTT).  
 
Immunoblotting  
Equal amounts of protein were separated in 8% self-made or 4-12% precast Bis-Tris-
glycine gels (Invitrogen, Novex), transferred onto PVDF nylon membrane (Millipore 
Immobilon-P, Bedford, USA) and stained with 0.2% Ponceau-S (Sigma, Bucks, 
Switzerland) in 7.5% TCA for confirmation of equal protein loading prior to blocking 
the membrane in 10% horse serum (or 1% BSA), TBS and 1% Tween-20. For 
immunoblotting, the following mouse monoclonal antibodies against TM1-3 (TM311, 
Sigma, Bucks, Switzerland, 1:1000), vinculin (hVIN-1, Sigma, Bucks, Switzerland, 
1:1000), a-tubulin (Ab-1, Oncogene, Dietikon Switzerland, 1:5000), RhoA (26C4, 
Santa Cruz Biotechnology, Heidelberg, Germany, 1:1000), P-ERK1/2 (Cell Signaling, 
Allschwil, Switzerland, 1:1000), FAK and phospho-Y397-FAK (BD Biosciences, 
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Germany, 1:1000); rabbit polyclonal antibodies, paxillin and phospho-Y118-paxillin 
(Abcam, Cambridge, UK, 1:1000), and ERK1/2 (Cell Signaling, Allschwil, 
Switzerland, 1:1000), phospho-S910-FAK (Biosource, Lucerne, Switzerland, 1:1000), 
phospho-S19-MLC (Santa Cruz Biotechnology, Heidelberg, Germany, 1:1000) and 
secondary HRP-coupled antibodies (Amersham, UK) were used. Binding of 
antibodies was detected with ECL-plus (Amersham, UK).  
 
Immunofluorescence 
Cells were serum-starved prior to plating on fibronectin and FN/TN for the indicated 
time points in serum free medium supplemented with the indicated growth factors. 
Cells were fixed in 4% PFA and stained with the indicated primary and secondary 
FITC-labeled antibodies or with TRITC-labeled phalloidin (Sigma, Bucks, 
Switzerland). Images were captured using a NIKON Diaphot300 (NIKON Video 
Microscope with Openlab program, Coventry, UK) at 400- and 1000-fold 
magnification (immunofluorescence) and  with a Leica LEITZ DMIL microscope 
(Wetzlar, Germany) at a 100-fold magnification for phase-contrast pictures. 
 
RhoA activation assay  
T98G cells (2 x 103) were serum starved for 18 h prior to plating onto fibronectin or 
FN/TN in 6-well dishes (10 cm2/well, Falcon) for 15 and 30 minutes or 4 h in serum 
free or LPA/PDGF-supplemented medium, washed with 3 ml ice-cold PBS prior to 
lysis in 70 µl Cell ice-cold lysis buffer per well (GLISA, Cytoskeleton, Lucerne, 
Switzerland). Lysates were adsorbed to rhotekin-bound plates (GLISA) with 
equalized protein amount (0.4-2.0 mg/ml) in the presence of binding buffer for 30 
minutes at 4°C. After washing, the plate was incubated with antigen-presenting buffer 
prior to incubation with an anti-RhoA primary antibody for 45 minutes. After 
incubation with a HRP-labelled secondary antibody, bound RhoA antibody was 
determined by measuring OD 490 nm. Positive and negative controls were provided 
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Cell migration assay 
Glass cover slips (10 mm2, medite Medizintechnik AG, Nunningen, Switzerland) were 
precoated with poly-L-lysin (0,01 %, mol wt 70000-150000, Sigma) for 1 h prior to 
successive coating with fibronectin, tenascin-C and BSA. Serum starved cells (1 - 2 x 
103 cells) were plated onto the cover slips for 4 h in serum free medium. Cells on the 
cover slip were transferred into FN/TN coated 6-well dishes (10 cm2, Falcon) for 12 
h, 24 h and 48 h in serum free medium, or in medium supplemented with EGF, LPA, 
PDGF and LPA/PDGF, respectively. Pictures were taken from three randomly 
chosen areas from the cover slips and cells were counted that had migrated into the 
6-well dish. 
 
Quantitative and semiquantitative RTPCR 
Total RNA was isolated from three independent plates using the RNeasy Mini Kit 
(Qiagen, Basel, Switzerland) and RNAse-free DNAse set (Qiagen, Basel, 
Switzerland) following the manufacturer’s instructions. From 0,5 –1 µg of total RNA 
single strand cDNA was generated by using the SuperScript III First-Strand 
Synthesis Super Mix (Invitrogen, Carlsbad, CA, USA) with random hexamers. 
Expression of the respective gene was detected by quantitative RTPCR on an ABI 
Prism 7000 TaqMan using SYBR green PCR MasterMix (Applied Biosystems, 
Warrington, Cheshire, UK) with the following primers (Supplemental Table 1). 
Primers were designed with the ABI Primer Express software (Applied Biosystems, 
Warrington, Cheshire, UK). Relative expression of the respective gene was 
determined after normalization to GAPDH and was calculated with the formula: 
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Supplemental Table 1    Primers used for quantitative SYBR green RTPCR 
Name Forward Reverse 
murine syndecan-4 GTATCCATGTCCAGCACTG ATGCGTAGAACTCATTGGTG 
murine syndecan-1 CACTTCTGTCATCAAAGAGGTTGT CTGTCCAAAAGGCTCTGAGAAG
murine syndecan-2 CCCAAAGTGGAAACCATGAC GCAAAGAGAAAGCCGATCAC 
murine paxillin CTACAGCTTCCCCAACAAGC CCCCCAAGGGAGTGTTATTT 
αTM GAGCGTCTGGCAACAGCTTT TCTTTTTGGGCTCGACTCTCA 
βTM TCAGACCGCAAATATGAAGAGGT TCCTTCCAGGATCACCAGCTT 
γTM GAGGTGGCTCGTAAGTTGGTG CTCTGTGCGTTCCAAGTCTCC 
RhoA GCAGGTAGAGTTGGCTTTATGG CTTGTGTGCTCATCATTCCGA 
GAPDH TCCTCTGACTTCAACAGCGACA CGTTGAGGGCAATGCCA 
chicken syndesmos AACTTCCTGGCCAACTCCTT GCGTATTCATTGCCTGCTCT 
 
 
Generation of gene knock-down and overexpressors 
T98G cells were stably transfected with shRNA constructs specific for aTM together 
with a pCIneo plasmid as described (Huang et al., 2001) (Supplemental Table 2) 
(SuperArray). Cells were subcloned and downregulation of aTM was determined by 
immunoblotting and real time RTPCR, respectively. Paxillin was transiently 
downregulated with siRNA oligo nucleotides (Supplemental Table 2). A plasmid with 
the chicken syndesmos sequence was cotransfected together with a pCIneo plasmid 
and G418 restistant cells were selected. Expression of the transgene was 
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Supplemental Table 2   Oligos used for knocking down gene expression 
sh-human αTM oligos 5`-CTGAGGATTCAGACCGCAAAT-3’ 
5`-AAGCACATCGCTGAGGATTCA-3’ 
sh-control Scrambled artificial sequence which does not match any human or 
mouse gene, not further disclosed by the manufacturer. 
si-Luciferase (control) Sense : CTTACGCTGAGTACTTCGAdTdT  
Antisense : TCGAAGTACTCAGCGTAAGdTdG  
si-murine paxillin oligos 
 
Sense : GAGCCCTCACCTACCGTCAdTdG  
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Cooperative signaling by LPA and PDGF induces cell spreading on a 
fibronectin/tenascin-C substratum  
We examined cell adhesion on FN/TN in the presence of different growth factors and 
observed that cells remained as round in the presence of LPA, PDGF-BB (PDGF) 
and EGF during 4 h after plating as in the absence of growth factors (Fig. 1A). This 
was in contrast to LPA/PDGF, where 78 % of cells spread on FN/TN in comparison 
to fibronectin (Fig. 1B). To understand how LPA/PDGF induced cell spreading on 
FN/TN, we used immunostaining and observed that cells formed vinculin containing 
focal adhesions and exhibited polymerised actin upon stimulation with LPA/PDGF, 
which was in contrast to serum free medium (Fig. 1C) and LPA and PDGF alone 
(data not shown), where cells were round and lacked these structures. By 
immunoblotting we determined expression of RhoA, FAK, paxillin and TM1. 
LPA/PDGF induced phosphorylation of FAK, paxillin and ERK1/2 and restored 
expression of TM1 and RhoA. This was in contrast to LPA or PDGF alone, where 
expression of these molecules remained significantly lower on FN/TN than on 
















 Fig. 1 Cooperative signaling by LPA and PDGF induces cell spreading on FN/TN and
restores adhesion signaling 
T98G cells were plated on fibronectin or FN/TN in serum free medium (no GF), or with EGF,
LPA, PDGF and LPA/PDGF for 4 h before documentation of cell shape (A), counting spread
cells in triplicates (B). 101
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Fig. 1 Cooperative signaling by LPA and PDGF induces cell spreading on FN/TN and restores
adhesion signaling 
T98G cells were plated on fibronectin or FN/TN in serum free medium (no GF), or with EGF, LPA,
PDGF and LPA/PDGF for 4 h before documentation of immunostaining for vinculin and polymerised
actin (C), lysis and immunoblotting for the indicated molecules (D) and RNA extraction followed by real
time RTPCR for αTM (E). Expression was normalized to GAPDH. Spread cells of three randomly
chosen fields at a magnification of 200-fold were counted.  
 
 
Since tenascin-C inhibits expression of TM1 by downregulating αTM expression, 
which subsequently reduces TM1 heterodimer protein stability (Lange et al., 2007), 
here, we examined how LPA/PDGF restored TM1 expression. By using real time 
RTPCR, we found that LPA/PDGF strongly increased low αTM expression, which 
exceeded levels on FN/TN in serum free medium (Fig. 1E). This was in contrast to 
βTM, γTM and RhoA RNA levels, that were not affected by tenascin-C nor by 
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correlated with activation of FAK, paxillin and ERK, and with high levels of RhoA and 
TM1. 
 
Syndecan-4 is upstream of RhoA, FAK and TM1, but is not required for 
LPA/PDGF-induced cell spreading on FN/TN 
So far we showed that RhoA, FAK and TM1 are targets of tenascin-C, the inhibition 
of which is linked to cell rounding by tenascin-C and, that LPA/PDGF blocks cell 
rounding on FN/TN through restoring expression and function of these molecules. 
Since tenascin-C-induced cell rounding could be abolished by activation of 
syndecan-4 (Huang et al., 2001; Orend, 2005; Midwood et al., 2004), here we 
wanted to know whether activation of syndecan-4 had an effect on RhoA, FAK and 
TM1. First, we confirmed that activation of syndecan-4 with FNIII13 restored 
spreading of T98G cells on a FN/TN substratum (Fig. 2A). This correlated with 
restored expression of RhoA, P-FAK and TM1 (Fig. 2B). By real time RTPCR we 
observed that FNIII13 increased αTM levels (Fig. 2C), which demonstrates that 
syndecan-4 regulates RhoA and FAK upstream of TM1 at αTM expression level, thus 
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 Fig. 2 Role of syndecan-4 in LPA/PDGF-induced cell spreading on FN/TN
T98G (A – C) were plated on the indicated substrata for 4 h in 1% FCS (A, B), serum free
medium (C) before documentation of cell adhesion (A), lysis and immunoblotting (B) and
RNA extraction and real time RTPCR for αTM (C). 104




By using wildtype MEFs and MEFs from syndecan-4 knock-out mice, we analysed 
whether the activation status of syndecan-4 is linked to cell spreading and 
expression of RhoA, P-FAK and TM1 expression in another cell system. Whereas 
FNIII13 restored cell spreading in wildtype MEFs to 55% of that of cells on 
fibronectin, FNIII13 failed to do so in MEF S4-/- (Supplemental Fig. 1A, B), which 
confirms that inhibition of syndecan-4 is the major mechanism of tenascin-C-induced 
cell rounding at an early time point of adhesion (Huang et al., 2001; , Midwood et al., 
2004). Similar to T98G cells, RhoA and P-FAK levels increased in wildtype MEFs in 
the presence of FNIII13 on FN/TN in comparison to its absence (Supplemental Fig. 
1C). In MEFs, expression of TM1-3 was downregulated on FN/TN, but was restored 
to normal levels with FNIII13. This was different to MEF S4-/-, where TM1-3 
expression was independent on the substratum (Supplemental Fig. 1C). In MEF S4-
/- cells RhoA, P-FAK and P-paxillin levels remained very low on all substrata 
including the FNIII13 supplemented FN/TN substratum. Collectively, these results 
suggest that syndecan-4 is required for activation of FAK and paxillin and for stable 
expression of RhoA and TM1, thus promoting cell spreading.  
 
To investigate whether LPA/PDGF-induced cell spreading on FN/TN is syndecan-4 
dependent, we analysed spreading of MEF S4-/- upon stimulation with LPA/PDGF. 
Whereas MEF S4-/- were round on FN/TN in the absence of growth factors, 58% of 
cells spread upon stimulation with LPA/PDGF in comparison to fibronectin (Fig. 2D, 
E). These data revealed, that signaling by LPA/PDGF is suffcient to induce spreading 
on FN/TN in the absence of syndecan-4, which suggests that LPA/PDGF can bypass 
syndecan-4 requirement for cell spreading. As determined by immunoblotting, 
stimulation by LPA/PDGF strongly induced phosphorylation of paxillin and ERK in 
MEF S4-/- (Fig. 2F) as well as in wildtype MEFs on FN/TN (data not shown). In 
summary, we showed that syndecan-4 regulates RhoA and FAK upstream of αTM 
expression. Moreover, signaling by LPA/PDGF appears to bypass syndecan-4 
requirement for cell spreading on FN/TN. This correlates with activation of paxillin, 
which points at paxillin as an important downstream target of LPA/PDGF-induced cell 
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Fig. 2 Role of syndecan-4 in LPA/PDGF-induced cell spreading on FN/TN 
MEF wt and MEF S4-/- cells (D) were plated on the indicated substrata for 4 h in  serum 
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 Fig. 2 Role of syndecan-4 in LPA/PDGF-induced cell spreading on
FN/TN 
MEF wt and MEF S4-/- cells (D – F) were plated on the indicated
substrata for 5 h in serum free medium in presence or absence of
LPA/PDGF (F) before documentation of lysis and immunoblotting (F)   
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Activation of paxillin through syndesmos bypasses syndecan-4 requirement 
for cell spreading 
To address the question whether syndecan-4 independent LPA/PDGF-induced cell 
spreading requires paxillin, we determined cell spreading in MEF S4-/- upon 
knocking down paxillin with siRNA oligonucleotides. By real time RTPCR (data not 
shown) and immunoblotting we confirmed efficient depletion of paxillin from the cells 
(Fig. 3A). Cells hardly attached and spread on fibronectin (data not shown) nor on 
FN/TN in the presence of LPA/PDGF (Fig. 3B), which demonstrates that paxillin is 





















 Fig. 3 Effect of paxillin and syndesmos on cell adhesion signaling upon plating on FN/TN  
Knock-down of paxillin by siRNA in MEF S4-/- (A) was determined by documentation of cell
shape (B). ext, we examined whether high expression of syndesmos, a paxillin binding linker 
etween integrin α5β1 and syndecan-4 may overcome cell rounding by tenascin-C. 
herefore, T98G cells ectopically expressing chicken syndesmos were generated 
nd expression of the construct was confirmed by semiquantitative RTPCR (Fig. 
C). T98G:syndesmos cells spread on FN/TN to a similar extent as on fibronectin, 
hich was different to tenascin-C, where cells remained round (Fig. 3D). Moreover, 
108
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T98G:syndesmos cells formed vinculin containing focal adhesions and actin 
filaments on FN/TN in serum free medium, which were absent from the parental cells  
 
(Fig. 3E). To address the mechanism of spreading on FN/TN upon ectopic 
expression of syndesmos, we determined expression of the tenascin-C targets TM1, 
RhoA, FAK and paxillin by immunoblotting. In contrast to tenascin-C, where 
phosphorylation or expression of these molecules was very low, levels of TM1, 
RhoA, P-FAK and P-paxillin were as high on FN/TN as on fibronectin upon ectopic 
expression of syndesmos (Fig. 3F). Together, these data suggest that syndesmos 
plays an important role in cell spreading on FN/TN, presumably by recruiting paxillin, 
FAK and other signaling molecules to the plasma membrane independent on 
syndecan-4, which initiates focal adhesion and actin stress fiber formation. Moreover, 











Fig. 3 Effect of paxillin and syndesmos on cell adhesion signaling upon plating on FN/TN  
Ectopic expression of syndesmos in T98G cells (C) was determined by immunoblotting and RTPCR. 
Documentation of the presence of actin stress fibers and focal adhesions by immunofluorescence (E), 
and expression of tenascin-C target molecules by immunoblotting (F). 
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D                                       T98G:Syndesmos 
Fig. 3 Effect of paxillin and syndesmos on cell adhesion signaling upon plating on FN/TN  
Ectopic expression of syndesmos in T98G cells was determined by documentation of cell shape (D). 
 
Expression of tropomyosin-1 is critical for LPA/PDGF-induced cell spreading 
on FN/TN  
Tenascin-C downregulates TM1 and, ectopic expression of TM1 restored cell 
spreading on FN/TN (Ruiz et al., 2004), suggesting that low TM1 levels are critical for 
tenascin-C-induced cell rounding. Here, we confirmed that elevated TM1 expression 
in T98G:TM1D10 cells promotes cell spreading on FN/TN, which is documented by 
formation of actin stress fibers and microtubules (Supplemental Fig. 2). A similar 
observation was made for REF52 cells, that were engineered to ectopically express 
TM1. In contrast to parental cells that remained round, REF:TM1 cells spread with 
actin stress fibers and focal adhesions on FN/TN (data not shown), confirming that 
repression of TM1 is a general mechanism of tenascin-C induced cell rounding. We 
wanted to know whether ectopically expressed TM1 had an effect on RhoA  
expression and phosphorylation of FAK. As shown in Fig. 4A, levels of RhoA and of 
phosphorylated FAK were restored in T98G:TM1D10 cells on FN/TN to levels as on 
fibronectin. These data suggest that TM1 is also upstream of FAK and RhoA, and 
supports our notion, that high and low P-FAK, RhoA and TM1 levels together, are 













































 Fig. 4 Effect of TM1 levels on LPA/PDGF-induced cell spreading on FN/TN
T98G cells with ectopic expression of βTM (T98G:TM1D10) (A) and knock-down of αTM (B)
were plated for 4 h in medium supplemented with 1% FCS (A), 10% FCS on plastic (B) or on
fibronectin in the absence or presence of tenascin-C (A), before lysis and immunoblotting (B).  
 
o examine whether high levels of TM1 are required for LPA/PDGF-induced cell 
preading, we generated cells stably suppressing αTM by shRNA and plated cell 
lones with 2 different shRNAs on FN/TN together with LPA/PDGF. Cells with aTM 
nocked down exhibited lowered TM1-3 expression and, thus mimicked TM1 
eterodimer downregulation by tenascin-C (Lange et al., 2007) (Fig. 4B). These cells 
ardly attached and did not spread on fibronectin in serum free medium (Fig. 4C), 
hich suggests that TM1-3 are required for cell spreading on fibronectin. In addition, 
e analysed αTM knock down cells did not spread on FN/TN together with 
PA/PDGF, which was in contrast to 80% of sh control cells that were triggered to 
pread on FN/TN upon stimulation with LPA/PDGF in comparison to cells on 
bronectin in serum free medium (Fig. 4C, D). This result suggests that high TM1 
vels are critical for LPA/PDGF-stimulated spreading on FN/TN.  
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Fig. 4 Effect of TM1 levels on LPA/PDGF-induced cell spreading on FN/TN
T98G cells with knock-down of αTM (B - E) were plated for 4 h in medium supplemented with 
LPA/PDGF (C) on fibronectin in the absence or presence of tenascin-C (C), before  immunofluorescence 
for polymerized actin (D).   
 
Next, we analysed expression of RhoA, P-FAK and P-paxillin in the αTM knock-down 
cells. LPA/PDGF elevated TM1 expression in the shaTM3D2 cells on both substrata 
(Fig. 4E) in comparison to serum free medium. This suggests that signaling by 
LPA/PDGF counteracts the knock-down of αTM. LPA/PDGF-associated increased 
TM1 levels correlated with enhanced levels of RhoA and P-FAK even in the αTM 
knock down cells. In contrast to the sh-control cells, in which LPA/PDGF triggered 
high phosphorylation of paxillin, P-paxillin was undetectable in all shαTM cells (Fig. 
4E and data not shown). This observation points again to paxillin as an important 
downstream effector of LPA/PDGF-induced spreading on FN/TN.  Together, our data  
suggest that TM1 expression is tightly linked to cell shape on FN/TN. Spread cells 
exhibited high TM1 levels, which was in contrast to round cells that showed low TM1 
expression on FN/TN. Whereas ectopic expression of TM1 restored expression and 
function of RhoA, FAK and paxillin, forced down-regulation of TM1 blocked cell 
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Fig. 4 Effect of TM1 levels on 
LPA/PDGF-induced cell spreading 
on FN/TN 
T98G cells with knock-down of αTM  
were plated for 4 h in medium 
supplemented with LPA/PDGF (E) on 
plastic on fibronectin in the absence or 
presence of tenascin-C, before lysis 
and immunoblotting. 
 
LPA/PDGF-specific expression of RhoA, P-FAK and TM1 is PI3K and MEK-
dependent 
By using chemical inhibitors we examined which pathway downstream of the 
receptors for LPA and PDGF is responsible for cell spreading on FN/TN. Cells were 
treated with inhibitors for PI3K (wortmannin), MEK (UO126), PLCγ (U73122), JNK 
(SP600125) and ROCK (Y27632) and, cell spreading and expression of RhoA, FAK 
and TM1 was analysed by immunoblotting. Inhibition of PI3K (Fig. 5A) and MEK 
(Fig. 5B) is documented by a lack of phosphorylation of downstream Akt and 
ERK1/2, respectively. We found, that whereas wortmannin did not affect spreading 
on fibronectin at this concentration (data not shown), it counteracted cell spreading 
induced by LPA/PDGF on FN/TN (Fig. 5C). This was in contrast to the other 
inhibitors that did not interfere with LPA/PDGF-induced cell spreading 
(Supplemental Fig. 3A). Upon inhibition of PI3K by wortmannin, levels of 
phosphorylated FAK and paxillin, and of RhoA and TM1 were very low or absent in 
cells plated onto FN/TN together with LPA/PDGF (Fig. 5D). Upon inhibition of MEK 
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by UO126, cells were elongated in the presence of LPA/PDGF (Fig. 5C). But, UO126 
did not only lower expression of TM1, it also reduced phosphorylation of FAK and  
 
paxillin and expression of RhoA on both substrata (Fig. 5E). Expression of these 
molecules apparently remained high enough to allow cell spreading on FN/TN (Fig. 
5C). Inhibition of PLCg and JNK did not compromise high levels of RhoA, TM1 and 
phosphorylated FAK by LPA/PDGF  (Supplemental Fig. 3B, C).  
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Fig. 5 LPA/PDGF-induced 
adhesion signaling is PI3K and 
MEK-dependent 
Cells were plated onto the two 
substrata for 1 h before addition of 
wortmannin (Wm) or UO126 for 
another 4 h in serum free medium or 
together with LPA/PDGF. (A-B) 
immunoblotting for the indicated 
molecules. 
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Fig. 5 LPA/PDGF-induced adhesion signaling is PI3K and MEK-dependent 
Cells were plated onto FN/TN for 1 h before addition of wortmannin (Wm) or UO126 
for another 4 h in serum free medium or together with LPA/PDGF. (C) documentation 
of cell shape.  
 





Since LPA/PDGF increased RhoA levels on FN/TN, we wanted to know whether 
LPA/PDGF had an influence on RhoA activation. Therefore, we measured GTP-
loading of RhoA in T98G cells on fibronectin or FN/TN in serum free medium. By 
ELISA for rhotekin-bound RhoA we observed that RhoA activation was 73, 70 and 
90% of that on fibronectin at 15 and 30 minutes and 4 h after plating, in serum free 
medium, respectively. Stimulation by LPA/PDGF insignificantly elevated rhotekin-
bound RhoA over that without growth factors (Supplemental Fig. 4A). These data 
suggest that activation of RhoA is independent on matrix adhesion in these cells. 
 
Next, we addressed the possibility that ROCK, a kinase involved in actin 
polymerisation downstream of RhoA is affected by tenascin-C and/or LPA/PDGF 
signaling. Upon plating together with the ROCK inhibitor Y27632, cells still spread on 
FN/TN. They exhibited protrusions resembling filopodia (Supplemental Fig. 4B). 
This change in cell shape supports inhibition of ROCK by Y27632. High expression 
of RhoA, phosphorylated FAK and TM1 remained unchanged on FN/TN together 
with LPA/PDGF upon ROCK inhibition. Whereas MLC, a downstream target of 
ROCK, was not phosphorylated on FN/TN in serum free medium, MLC got 
phosphorylated with LPA/PDGF on FN/TN. This was even enhanced by Y27632 
leading to as high P-MLC levels on FN/TN as on fibronectin in serum free medium. 
We conclude, that signaling by LPA/PDGF restored MLC phosphorylation by a 
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Fig. 5 LPA/PDGF-induced adhesion signaling is PI3K and MEK-dependent 
Cells were plated onto the two substrata for 1 h before addition of wortmannin (Wm) or 
UO126 for another 4 h in serum free medium or together with LPA/PDGF. (D, E) 





Tenascin-C promotes glioma cell migration upon LPA/PDGF stimulation in a 
ROCK and MEK dependent manner 
So far we showed that LPA/PDGF induces cell spreading on FN/TN. Given, that an 
anti-adhesive tenascin-C substratum can promote cell migration (Zagzag et al., 2002; 
1992; Tamaoki et al. 2005; Nishio et al., 2005), we asked whether LPA/PDGF affects 
cell migration on FN/TN. Migration of T98G glioblastoma cells was monitored on 
FN/TN upon stimulation with EGF, LPA and PDGF. In contrast to immobile cells in 
the absence of growth factors (Fig. 6A), LPA and PDGF alone (data not shown), 
LPA/PDGF stimulated cell migration after 24 h, which was even more enhanced after 
48 h (Fig. 6A, D). After 48 h cells presumably secreted factors that induced migration 
under serum free conditions on FN/TN and, thus promoted cell migration at this time 
point but, with a rounded cell shape, which was different to an elongated shape upon 
stimulation with LPA/PDGF. Interestingly, EGF completely blocked migration that 
occurred at 48 h in serum free medium (Fig. 6B). These data show that LPA/PDGF 
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migration on a tenascin-C substratum can be enhanced or blocked depending on the 
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Fig. 6 Induction of cell migration by tenascin-C upon stimulation with LPA/PDGF  
Cell migration from a glass cover slip coated with PLL, fibronectin and tenascin-C onto a 
FN/TN-coated plastic surface is documented for T98G in the presence of the indicated 
supplements. Cell morphology (A) and numbers of migrated cells (B) is shown. Cells having 
passed the rim (margin highlighted) from three randomly chosen areas were counted in 
triplicates.  





Next, we asked whether LPA/PDGF-induced migration was affected by an altered 
expression and function of syndesmos and TM1. Therefore, migration of the 
indicated cells on a FN/TN substratum was determined in the absence or presence 
of LPA, PDGF (data not shown) and LPA/PDGF (Supplemental Fig. 5). Whereas all  
cells did not migrate in the absence of growth factors, control T98G:pCIneo and 
T98G:sh control cells migrated very well on FN/TN upon stimulation with LPA/PDGF 
in a time-dependent manner (Supplemental Fig. 5). In contrast to the control cells, 
T98G:syndesmos, T98G:TM1D10 and T98G:shαTM3D2 cells, did at most only 
marginally move in the presence of LPA/PDGF during 48 h. These data emphasize 
that tenascin-C and LPA/PDGF collaborate in cell migration. Moreover, strong 
adhesion through ectopic expression of syndesmos or βTM, as well as reduced 
adhesion upon suppression of TM1-3 was not compatible with LPA/PDGF-stimulated 
cell migration on FN/TN.  
 
To address which signaling downstream of LPA/PDGF triggers cell migration on 
FN/TN, we analysed cell migration upon inhibition of ROCK and MEK with Y27632 
and UO126, respectively. Although inhibition of ROCK did not affect cell spreading 
after 4 h (Supplemental Fig. 4A), it largely compromised LPA/PDGF stimulated cell 
migration on FN/TN at all time points (Fig. 6C, D). Similarly, cells did not migrate on 
FN/TN in the presence of LPA/PDGF upon inhibition of MEK with UO126 (Fig. 6C, 














































                         
QuickTime™ and a
TIFF (LZW) decompressor
are needed to see this picture.
 





















Fig. 6 Induction of cell migration by tenascin-C upon stimulation with 
LPA/PDGF  
Cell migration from a glass cover slip coated with PLL, fibronectin and tenascin-C 
onto a FN/TN-coated plastic surface is documented for T98G in the presence of 
the indicated supplements. Cell morphology (C) and numbers of migrated cells 
(D) is shown. Cells having passed the rim (margin highlighted) from three 























Fig. 7 Cooperative signaling by LPA/PDGF bypasses syndecan-4 requirement for cell 
spreading 
(A) Upon adhesion to fibronectin, simultaneous activation of integrin α5β1 and syndecan-4 
leads to the establishment of focal adhesions. FAK is one of the first effectors to become 
phosphorylated and RhoA is trageted to the membrane where it is involved in actin 
polymerisation. Our data confirm that RhoA is an important downstream effector of syndecan-4 
(Saoncella et al., 1999). Syndesmos might bridge syndecan-4 to integrins through its binding to 
syndecan-4 and to paxillin (Bass and Humphries, 2001). Tenascin-C competes with binding of 
syndecan-4 to FNIII13 within the 2nd heparin binding site of fibronectin, thus causing cell 
rounding on FN/TN, which is due to a lack of signaling from syndecan-4 (Huang et al. 2001). 
This prevents activation of FAK and focal adhesion formation. In addition, on a FN/TN 
substratum actin polymerisation and actin filament stabilisation is impaired by enhanced 
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Fig. 7 Cooperative signaling by LPA/PDGF bypasses syndecan-4 requirement for cell 
spreading 
(B) Cooperative signaling by LPA and PDGF bypasses syndecan-4 requirement for cell spreading 
on FN/TN by activating FAK and paxillin, restoring phosphorylation of MLC and expression of RhoA 
and TM1. This involves PI3K and MEK, since spreading was blocked by specific inhibitors. Thus, 
actin polymerisation, filament stabilisation and contractility is induced by LPA/PDGF signaling and 
thus triggers cell spreading on FN/TN. Upon stimulation of the receptors for LPA and PDGF, 
spreading on FN/TN triggers enhanced migration on this substratum. This effect is independent of 
syndecan-4, since it occurs in the absence of syndecan-4 expression. Our data confirm that 
syndesmos plays a crucial role as linker between syndecan-4 and integrin α5β1, since ectopic 
expression of syndesmos restored cell spreading on FN/TN. Knock down of paxillin and αTM 
prevented LPA/PDGF-induced cell spreading on FN/TN. Ectopic expression of TM1 restored cell 
spreading on FN/TN presumably through a feedback mechanism that leads to FAK activation and 
RhoA stabilisation on FN/TN. Our data showed that signaling from EGF sustained cell rounding by 
tenascin-C, whereas LPA/PDGF signaling induced cell spreading and triggered cell migration. 
Adhesion or release from a tenascin-C enriched microenvironment has implications in tumor 
progression as well as in stem cell niche identity.  Inhibition or downregulation and activation or 















Cell adhesion to an ECM substratum can be modulated by growth factors. This 
applies in particular to cell rounding by tenascin-C and provides a means to adjust 
the adhesive properties of the microenvironment within a tissue according to the 
physiological status. A substratum of tenascin-C alone or in combination with 
fibronectin is anti-adhesive for most cells. Tenascin-C competes with syndecan-4 
binding to fibronectin, thus preventing activation of syndecan-4 and causing cell 
rounding. Here, we proved that inhibition of syndecan-4 is the major mechanism of 
tenascin-C-induced cell rounding at an early time point of adhesion, since MEFs that 
lacked syndecan-4 did not spread on FN/TN upon activation with the syndecan-4 
ligand FNIII13 4 h after plating. This was opposite to cells expressing syndecan-4, 
which did spread on FN/TN in the presence of FNIII13 (Supplemental Table 3).  
 
In addition to activation of syndecan-4, here we showed that LPA/PDGF induces 
spreading on FN/TN, which was in contrast to LPA or PDGF alone, where cells 
remained round. We wanted to know whether LPA/PDGF-induced spreading was 
syndecan-4 dependent and found that cells with no syndecan-4 expression still 
spread on FN/TN upon stimulation with LPA/PDGF. We examined the possibility that 
elevated levels of syndecan-1 and –2 potentially compensated for the lack of 
syndecan-4, but expression of these syndecans as determined by real time RTPCR 
was not increased in MEF S4-/- cells over that in wildtype MEFs (data not shown).  
Our data support the possibility that signaling from LPA/PDGF bypasses the 
requirement of syndecan-4 for cell spreading on FN/TN. We analysed the underlying 
mechanism and demonstrate that RhoA, FAK, paxillin and TM1 are critical targets of 
tenascin-C. We showed that expression of RhoA and TM1 as well as 
phosphorylation of FAK and paxillin were very low on FN/TN in the absence of 
growth factors. But, upon stimulation with LPA/PDGF, expression and 
phosphorylation of these molecules was reverted to high levels as on fibronectin 
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Next, we asked whether restored expression and activation of these molecules was 
necessary for LPA/PDGF-induced cell spreading on FN/TN. First, we addressed a 
potential role of RhoA. Whereas the levels of RhoA significantly dropped on FN/TN,  
 
 
activation of RhoA as determined by the amount of GTP-loading, was not lowered up 
to 4 h. Apparently, activation of RhoA was independent on cell shape, and even very 
low RhoA levels were sufficient for actin polymerisation in these cells. Inhibition of 
ROCK, a downstream target of RhoA did not interfere with LPA/PDGF-induced 
spreading but rather enhanced spreading, which was also reflected by an increased 
MLC phosphorylation. This result points to a ROCK-independent mechanism of 
LPA/PDGF-induced MLC phosphorylation. It is possible that the observed enhanced 
ERK1/2 activation by these growth factors bypassed ROCK requirement for actin 
polymerization (Ridley et al.,2001). In contrast to RhoA and ROCK, knockdown of 
paxillin abolished spreading by LPA/PDGF (Fig. 7B), which points at paxillin as a 
major critical effector of tenascin-C-induced cell rounding. 
 
Since syndesmos binds paxillin and thus may recruit syndecan-4 into focal 
adhesions (Bass and Humphries, 2001), we wondered whether ectopic expression of 
syndesmos had an effect on cell rounding by tenascin-C. We found that ectopically 
expressed syndesmos restored cell spreading on FN/TN, but not on tenascin-C. 
Again, cell shape correlated with expression and activation of FAK, paxillin, RhoA 
and TM1 (Supplemental Table 3). Spread T98G:syndesmos cells exhibited a high 
phosphorylation of FAK and paxillin and high expression of RhoA and TM1 on 
FN/TN. We conclude, that syndesmos may provide a platform for recruitment of 
paxillin and other adaptor proteins into focal adhesions, thus promoting cell 
spreading. High syndesmos levels may bypass syndecan-4 requirement for cell 





Whereas TM1 levels were very low on FN/TN in the absence of growth factors, they 
were as high on this substratum as on fibronectin upon stimulation with LPA/PDGF. 
We confirmed that a forced expression of TM1 restored cell spreading (Ruiz et al., 
2004), and found that this correlated with restored RhoA levels and FAK 
autophosphorylation. This result suggests a positive feedback mechanism by which 
TM1 sustains RhoA expression, actin filament stabilisation and FAK activation. That 
tropomyosin levels are critical was shown by knocking down expression of αTM, 
 
 
                                                 Results: Promotion of a motile phenotype by tenascin-C and LPA/PDGF 
 
which interfered with LPA/PDGF-induced cell spreading on FN/TN. By real time 




stability level, since expression of βTM, that encodes TM1, was not altered (Lange, 
data not shown). In contrast to βTM, expression of αTM, which codes for TM2 and 
TM3, was regulated by cell adhesion and growth factors. Expression of αTM was low 
on FN/TN and was restored to levels as on fibronectin with FNIII13 as well as with 
LPA/PDGF. High αTM levels apparently promoted stabilisation of TM1 heterodimers.  
 
We addressed the question which signaling events induced by LPA/PDGF were 
responsible for a restored expression and function of tenascin-C target molecules. By 
using chemical inhibitors, we identified PI3K and MEK as downstream signaling 
molecules, that are essential for LPA/PDGF-induced spreading on FN/TN. This was 
different to PLCγ and JNK, inhibition of which did not block LPA/PDGF-induced 
spreading (Supplemental Table 3). Although PLCγ is important in syndecan-4 
mediated spreading, its activation does not appear to be required in the presence of 
LPA/PDGF. We observed that spreading induced by LPA/PDGF was different to that 
induced by EDNRB. Whereas EDNRB-induced spreading was dependent on PLCγ 
and JNK, but independent on MEK (Lange et al., 2007), here we demonstrated an 
opposite mechanism for LPA/PDGF-induced spreading, that was independent of 
PLCγ and JNK, but dependent on MEK. Spreading in both conditions was PI3K 
dependent. We conclude, that at least two separate mechanisms exist that overcome 
tenascin-C induced cell rounding, which could be relevant in human cancers. 
 
We wanted to know whether LPA/PDGF signaling potentially contributes to tumor 
progression in a tenascin-C context. Since the acquisition of a motile phenotype is a 
prerequisite for invasion and metastasis, we examined cell migration in the presence 
of tenascin-C and LPA/PDGF, and observed that combined signaling by both growth 
factors strongly induced cell migration on FN/TN. We identified a mechanism by 
which tenascin-C collaborates with LPA/PDGF signaling and thus stimulates cell 
migration. This mechanism includes activation of FAK, paxillin and ERK1/2. 
Moreover, LPA/PDGF signaling also induced actin remodeling by restoring 
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stimulated actin polymerisation, filament stabilisation and contractility on FN/TN, 
which links to enhanced cell migration. Our data suggest that inhibition of syndecan-
4 by tenascin-C as well as remodeling of the actin cytoskeleton by LPA/PDGF 
signaling is important for cell migration on FN/TN (Fig. 7B). This mechanism may  
 
contribute to tumor progression and may explain a malignant aspect of tenascin-C in 
cancer. 
 
Here, we showed that tenascin-C collaborates with LPA/PDGF signaling. This 
collaborative signaling might also be relevant for the understanding of the role of 
tenascin-C in the neuronal stem cell niche, where maintenance of the 
oligodendrocyte precursor status and cell responses toward PDGF were impaired in 
the absence of tenascin-C (fFrench-Constant). Since we observed that syndecan-4 
synergises with LPA/PDGF-mediated spreading on FN/TN, it will be interesting to 
see whether OP responsiveness toward PDGF involves syndecan-4 in a tenascin-C 
context. Our data also suggest that the adhesive strength of tenascin-C is strongly 
influenced by additional signals. Whereas, LPA/PDGF renders tenascin-C adhesive 
and promotes migration, EGF supports the anti-adhesive properties of tenascin-C 
and fails to promote migration in a fibroblastoid manner. Thus, growth factors may 
determine whether cells remain in the stem cell niche and in the tumor tissue, 
respectively. At the mechanistic level, this might be linked to syndesmos, FAK, 
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Supplemental Fig. 1 Cell spreading and associated signaling in MEF wt and MEFS4-
/- on FN/TN upon activation of syndecan-4 with FNIII13.  
Wildtype MEFs (MEF wt) and MEFs lacking syndecan-4 (MEF S4-/-) were plated on the 
indicated substrata for 4 h in serum free medium. (A) documentation of cell shape, (B) 
number of spread cells, (C) immunoblotting for the indicated molecules. 
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Supplemental Fig. 2 Effect of TM1 expression levels on cell adhesion to FN/TN 
Cells ectopically expressing βTM (T98G:TM1D10) or pCIneo (T98G:pCIneo) were plated on 































Supplemental Fig. 3 Effect of signaling inhibitors on LPA/PDGF-induced cell spreading 
on FN/TN  
T98G cells were plated on fibronectin (data not shown) or FN/TN together with LPA/PDGF and 
inhibitors for PLC (U73122) and JNK (SP600125) (A) before lysis and immunoblotting (B, C). 
U73122 was added together with LPA/PDGF (lanes 3 and 4) or 15 minutes before addition of 
LPA/PDGF (lanes 5 and 6) (C). Note, that both conditions of JNK inhibition did not affect cell 
spreading by LPA/PDGF. 
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Supplemental Fig. 4 RhoA activation and ROCK inhibition on FN/TN 
Cells plated for the indicated time points on fibronectin in the absence or presence 
of tenascin-C together with LPA/PDGF or no growth factors were lysed and GTP-
bound RhoA was detected upon binding to plastic-adsorbed rhotekin by ELISA for 
RhoA (A). Cells plated together with the ROCK inhibitor Y27632 (B) were lysed and 
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Supplemental Fig. 4 RhoA activation and ROCK inhibition on FN/TN 
Cells plated for the indicated time points on fibronectin in the absence or presence 
of tenascin-C together with LPA/PDGF or no growth factors were lysed and GTP-
bound RhoA was detected upon binding to plastic-adsorbed rhotekin by ELISA for 
RhoA (A). Cells plated together with the ROCK inhibitor Y27632 (B) were lysed and 















Supplemental Fig. 5 Cell migration on FN/TN upon stimulation with LPA/PDGF and 
modulation of syndesmos and tropomyosin expression 
Cell migration of the indicated cell lines on FN/TN is documented in the presence of LPA/PDGF in 
comparison to serum free medium at the indicated time points. Whereas 1000 pCIneo and shRNA 
control cells were plated, 2000 cells were seeded for the other cell lines. Note, that very little 
T98G:syndesmos, T98G:TM1D10 and T98G:αTM3D2 cells migrated despite the presence of twice 























































Supplemental Table 3 








Summarised are cell spreading and activation of downstream effectors presented in this study. The 
following cells were used: T98G parental cells or control cells stably expressing pCIneo or shcontrol 
RNA (T98G), T98G cells stably expressing syndecan-4 shRNA knock-down (T98G:sh S4), dominant 
negative FAK (CD2-FAKYF), syndesmos (T98G:syndesmos), TM1 (T98G:TM1 D10), αTM shRNA 
knock-down (T98G:shαTM), wildtype mouse embryo fibroblasts (MEF wt) and MEFs from syndecan-4 
knock out mice (MEF S4-/-). Knock down of paxillin was accomplished with transient siRNA expression. 
The presence (1) or absence (0) of cell spreading (Spreading), on fibronectin/tenascin-C is indicated as 
deduced from immunofluorescent staining for polymerised actin and for vinculin or by determination of 
cell shape by phase contrast microscopy. Experiments were done in the absence of growth factors (no 
GF) or upon addition of EGF (epidermal growth factor), LPA (lysophosphatidic acid) or PDGFBB 
(PDGF). Data on the effect of the indicated inhibitors Wm (PI3K), UO126 (MEK), SP600125 (PLCγ), 
U73122 (JNK) and Y27632 (ROCK) are shown on phosphorylation of FAK at Y397 (P-FAK), and 
expression of RhoA and TM1 in cells grown on fibronectin/tenascin-C. Expression on FN/TN reached 
levels as on fibronectin (1) and, was very low or absent (0), respectively. a) addition of cells to a 
FN/TN/FNIII13 substratum. b) receptors for LPA and PDFG-BB. c) elongated motile cell shape. 












Cell adhesion to ECM involves signaling mechanisms which control attachment, 
spreading and the formation of focal adhesions and stress fibers (Woods et al., 
2000). During tumor progression, some of the primary tumor cells as well as the 
tumor microenvironment undergo characteristic molecular changes, which are 
essential for the metastatic dissemination of tumor cells. Tumor cell-intrinsic 
alterations include the loss of cell polarity and alterations in cell-cell and cell-matrix 
adhesion as well as deregulated receptor kinase signaling, which together support 
detachment, migration and invasion of tumor cells (Kopfstein and Christofori, 2006). 
In addition to cell-intrinsic changes, alterations in the tumor microenvironment are 
causally linked to tumor progression. Tenascin-C alone or in combination with 
fibronectin is anti-adhesive for most cells and prevents activation of syndecan-4, 
which causes cell rounding. Previously, it was shown that the function of FAK (Huang 
et al., 2001; Orend et al., 2003), RhoA (Wenk et al., 2000), and TM1 (Ruiz et al., 
2004) is compromised in cells grown on a mixed substratum of FN/TN. This occurred 
in a syndecan-4-dependent manner.  
 
Here, I investigated the mechanism, by which tenascin-C inhibits the formation of 
focal adhesions and actin stress fibers, and how tenascin-C affects expression and 
function of the three downstream targets FAK, RhoA and TM1. First, I examined 
whether inhibition of syndecan-4 by tenascin-C is potentially linked to reduced 
expression of RhoA and TM1 and inhibition of FAK. Indeed, MEFs that lacked 
syndecan-4 did not spread on FN/TN upon activation of syndecan-4 with its ligand 
FNIII13 4h, and this was linked to the lack of FAK activation. In contrast, syndecan-4 
expressing cells spread on FN/TN in the presence of FNIII13, and exhibited a 
restored expression and function of FAK, RhoA and TM1. Thus, repression of FAK, 
RhoA and TM1 could explain the lack of actin stress fiber and focal adhesion 
formation on FN/TN. Syndecan-4, working in cooperation with the α5β1 integrin, can 
stimulate a Rho-dependent pathway, that elicited focal adhesion and actin stress 
fiber formation in CBD-adherent cells (Saoncella et al., 1999). Furthermore, 
syndecan-4 signaling can be bypassed in CBD-adherent fibroblasts by directly 
stimulating the GTPase Rho with LPA (Saoncella et al., 1999). These data indicate 
an important role of syndecan-4 in RhoA activation. In addition, syndecan-4 interacts  
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with important cytoplasmic adaptor proteins such as paxillin. Paxillin binds several 
other focal adhesion-associated proteins such as vinculin, FAK and syndesmos.  
 
The actin cytoskeleton plays a central role in the regulation of cellular processes 
linked to metastasis including cell proliferation, apoptosis, anchorage-independent 
cell growth, cell migration, and invasion (Jaffe and Hall, 2002). TMs play a major role 
in regulating the actin cytoskeleton, by stabilizing actin filaments during actin 
polymerization (Cooper, 2002), and inhibition of actin depolymerization from the 
pointed end. Since tenascin-C downregulated TM1-3, I analyzed the role of 
tropomyosins in cell adhesion in the presence of tenascin-C in more detail. Published 
data suggest that TM1 expression and function is regulated by at least two pathways 
that involve ROCK and MEK. Since the ERK/MAPK signaling pathway is hyper-
activated in T98G glioblastoma cells on FN/TN (Ruiz et al., 2004), it is possible that 
this signaling contributes to repression of TM1 by tenascin-C (Orend, 2005). This 
possibility was supported by the observation that inhibition of MEK caused high 
levels of TM1 and resulted in cell spreading on FN/TN (Lange et al., 2007). The 
RhoA downstream effector ROCK also seems to be required for TM1 expression, 
since  inhibition of ROCK decreased TM1 expression (Janssen et al., 2003; Pawlak 
and Helfman, 2002a, 2002b). But, inhibition of ROCK did not interfere with high TM1 
expression upon stimulation with LPA/PDGF on FN/TN. Signaling by LPA/PDGF 
potentially compensated for the lack of a signal downstream of ROCK. Epigenetic 
mechanisms involving de novo methylation and acetylation of the TM1 promotor 
region have been shown to contribute to the loss of TM1 function in breast cancer 
cells (Bharadwaj and Prasad, 2002). I was interested  to know whether promoter 
methylation of TM1 in T98G cells could be involved in TM1 downregulation on 
FN/TN. In collaboration with Mirco Meningatti (research group of Prof. Schär, 
University of Basel), a methylation-specific PCR showed no changes in promoter 
methylation up to 6 days of culture (unpublished results). It is possible that the 
chosen time points were not long enough, therefore a potential epigenetic regulation 
of TM1 by tenascin-C  should be addressed in the future. 
 
Whereas expression of TM1 was not regulated by tenscin-C at the transcriptional 
level, it turned out that tenascin-C repressed RNA levels of two other HMW 
tropomyosins, TM2 and TM3, which are far less expressed in T98G cells than TM1. 
Apparently, lowered levels of TM2 and TM3 affected TM1 protein heterodimer 
stabilization through proteasomal degradation, that was largely enhanced on FN/TN.  
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Enhanced protein degradation by tenascin-C was supported by the observation that 
inhibition of the proteasome by the inhibitor ALLN, restored TM1 expression on the 
mixed substratum (Lange et al., 2007). These data suggest that tenascin-C does not 
only repress gene expression of HMW tropomyosins but also enhances their 
proteasome-mediated protein degradation. Repression of TM1 with tumor 
suppressor-like activity, by tenascin-C might be relevant in cancer, since low levels of 
TM1 can protect breast cancer cells from apoptosis (rev in Orend, 2005). 
 
Here, it was shown that concomittant restoration of the expression and function of all 
three downstream molecules FAK, RhoA and TM1, is necessary to induce cell 
spreading on a FN/TN substratum, which points at these molecules as a minimal set 
of important targets of tenascin-C. I observed that activation of EDNRB induced 
spreading in the presence of tenascin-C, which was dependent on PI3K, PLC and 
JNK, since chemical inhibitors of these enzymes blocked EDNRB-induced cell 
spreading on FN/TN. Signaling by EDNRB was linked to activation of FAK and 
paxillin as well as to restoration of TM1 and RhoA expression, again supporting the 
notion that inactivation of these molecules is critical for tenascin-C-induced cell 
rounding (Lange et al., 2007). Whereas phosphorylation of FAK at S910 and of 
paxillin at Y118 was absent or very low in the presence of tenascin-C in serum-free 
medium, EDNRB signalling restored phosphorylation in FAK and paxillin. It is 
possible that phosphorylation of FAK at S910 occurs through ERK2, and that P-
S910FAK phosphorylates paxillin, thus restoring cell spreading on FN/TN. 
Localization of paxillin into focal adhesions is dependent on syndecan-4, which 
involves binding of syndesmos to syndecan-4. But tenascin-C impairs syndecan-4 
activation and prevents localization of paxillin into focal adhesions. Thus, EDNRB 
activation restores focal adhesion formation on the mixed FN/TN substratum 
presumably through bypassing the requirement of syndecan-4 for the recruitment of 
paxillin into focal adhesions.  
 
In addition to EDNRB, concomittant activation of the receptors for LPA and PDGF 
also enabled cells to spread on a FN/TN substratum by a mechanism, which again 
involved restoration of the expression and function of FAK, RhoA and TM1. By using 
cells lacking syndecan-4, it was observed that LPA/PDGF also bypassed the 
requirement of syndecan-4 in cell spreading in the presence of tenascin-C. 
Knockdown of paxillin prevented LPA/PDGF-induced spreading in these cells on a  
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mixed substratum, which suggest an essential role of paxillin in LPA/PDGF-induced 
restoration of cell spreading on FN/TN.  
 
I observed, that TM1 levels were tightly linked to expression of RhoA and activation 
of FAK, which suggests an interdependent regulation of these molecules. This 
interdependent regulation could involve molecules that bind syndecan-4 such as Hic-
5 and the GTPase dynamin II (Yoo et al., 2005). Upon treatment with LPA, dynamin 
II and Hic-5 become associated with syndecan-4 at focal adhesion sites. RhoA, 
which acts upstream of TM1, and TM1 itself are strongly involved in the dynamic 
regulation of the actin cytoskeleton. Thus, it is possible that expression of RhoA and 
TM1 is similarly regulated. This possibility is supported by the results that were 
obtained for several cell lines including REF52, MEF and T98G glioblastoma cells, 
which show a concomittant expression of both molecules under the chosen 
conditions. The integrin-linked kinase (ILK) that co-localizes with paxillin in focal 
adhesions (Nikolopoulos and Turner, 2001) is another candidate that could be 
involved in cell adhesion on FN/TN. In many cellular processes such as cell 
migration, ILK, FAK and RhoA work together through paxillin.  
 
Whereas the levels of RhoA expression significantly dropped on FN/TN, an activation 
of RhoA was not lowered on this substratum in comparison to fibronectin up to 4h. 
Substratum-independent activation of RhoA may be accomplished in these cells 
through several mechanisms that potentially involve mDia and MTs (Wheeler and 
Ridley, 2004; Palazzo et al., 2001; Fukata et al., 2003), Rac (Hall, 1998), which is 
active on FN/TN (Orend, 2005), as well as a  rigid cortex in round cells (Ren et al., 
1999; Maddox and Burridge, 2003; Burridge and Wennerberg, 2004). Inhibition of 
ROCK, a downstream target of RhoA did not interfere with LPA/PDGF-induced 
spreading but enhanced spreading, which was also reflected by an increased MLC 
phosphorylation. This result points at a ROCK-independent mechanism of MLC 
phosphorylation on a FN/TN substratum upon stimulation with LPA/PDGF. 
Explanations for this result could be the ability of PDGF to induce autocrine signaling 
through both PDGFRs as well as paracrine signaling, which lead to activation of 
MAPK and PI3K signaling pathway (Kim et al., 2007; Lokker et al., 2002; Cao et al, 
2004).  Cell contractility necessary for migration, results in actin-myosin interactions 
and phosphorylation of MLC.  LPA induces the activity of both, the downstream 
effector ROCK and mDia. Upon inhibition of ROCK, mDia could induce actomyosin-
based contractility, which may result in phosphorylation of MLC (Wheeler and Ridley,  
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2004) independent of ROCK. Furthermore, LPA was identified to induce the 
formation of stable MTs (Palazzo et al., 2001), which are co-localized with actin 
filaments during cell migration and result in phosphorylation of MLC.  
 
Activation of the receptors for ET-1 (EDNRB), and LPA/PDGF induced spreading in 
the presence of tenascin-C by distinct pathways. Whereas EDNRB-induced 
spreading was dependent on PI3K, PLC and JNK, but not on MEK, LPA/PDGF-
induced spreading was dependent on PI3K and MEK, but not on PLC and JNK. 
Signaling by these factors was linked to activation of FAK and paxillin and, 
restoration of RhoA and TM1 expression. Together, these results suggest that at 
least two (and presumably many more) mechanisms exist that modulate the 
adhesive strength of a FN/TN substratum. Thus, combined signaling from ECM and 
growth factors can modulate cell adhesion and migration.  
 
Ruiz et al. (2004) described an enhanced expression of EDNRA in the presence of 
tenascin-C for later time points after seeding. Here, I demonstrated that EDNRA 
signaling is linked to cell rounding on a FN/TN substratum through inhibition of FAK 
and paxillin and repression of RhoA and TM1. Because activation of EDNRA and 
MEK downregulates TM1 expression (Janssen et al., 2003; Pawlak and Helfman, 
2002; Pawlak et al., 2004), I examined whether EDNRA-associated cell rounding on 
FN/TN was dependent on MAPK signaling. Indeed, inhibition of MEK with UO126 
blocked EDNRA-induced cell rounding and induced cell spreading, that was linked to 
a restored phosphorylation of FAK and a stable expression of RhoA and TM1. Thus, 
the results link TM1 and RhoA protein stability to EDNRA signaling (Lange et al., 
2007). Collectively, these data suggest that inhibition of syndecan-4 is responsible 
for initial cell rounding and that upon induction of EDNRA by tenascin-C, EDNRA 
prevents cell spreading on a FN/TN substratum at later time points. EDNRA-
associated cell rounding on FN/TN seems to be independent on syndecan-4, since it 
still occured in MEFs lacking syndecan-4 (recent not published data). 
 
In gliomas and other cancers we found a high expression of tenascin-C and EDNRA, 
that correlated with more advanced stages. This observation supports the possibility 
that tenascin-C potentially promotes tumor progression through EDNRA (Lange et 
al., in preparation). Numerous tumors, including carcinomas of the lung (Ahmed et 
al., 2000), prostate (Nelson et al., 2000), and ovary (Bagnato et al., 1999) produce 
one or more endothelins and their receptors (Nelson et al., 2003). They play an  
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autocrine and paracrine role in regulating growth of tumor and tumor associated 
cells, may inhibit apoptosis (Grimshaw et al., 2002) and promote angiogenesis 
(Bagnato et al., 2002). Therefore, these findings support notions about a critical role 
for the ET1/EDNRA axis during tumor progression that might be linked to tenascin-C 
(Rosano et al., 2006). The ET-1/EDNRA autocrine pathway was shown to be 
involved in epithelial-to-mesenchymal transition (EMT) in ovarian tumor cells. By 
using two pharmacologic antagonists of EDNRA: BQ123, a selective antagonist, and 
ABT-627, a small molecule that potently and selectively inhibits ET1 signaling at the 
level of interaction with EDNRA (Rosano et al., 2003), both cause inhibition of 
spontaneous growth rate in ovarian cancer primary cultures and cell lines (Rosano et 
al., 2005). In contrast, induction of EDNRB pathway promoted tumorigenesis upon 
activation by ET1 or ET3 in human cutaneous melanomas (Spinella et al., 2007; 
Bagnato et al., 2004). Blockage of EDNRB by a peptide antagonist BQ788 resulted 
in growth inhibition and death of melanoma cells in vivo and in vitro (Lahav et al., 
1999). Moreover, A-192621, a selective and orally active nonpeptide EDNRB 
antagonist (Griswold et al., 1999), inhibited cell proliferation and melanoma growth in 
nude mice (Bagnato et al., 2004). Thus, pharmacological interruption of both EDNRA 
and EDNRB signaling together with tenascin-C may represent a potent novel 
therapeutic strategy in the treatment of certain cancers.  
 
Gliomas represent about half of all brain tumors and glioblastoma multiforme is 
thought to be the most malignant and common intracranial tumor (Vandenberg, 
1992). Moreover, tenascin-C is a very prominent molecule of the glioma ECM. 
Although generally not metastatic, glioblastoma cells exhibit highly migratory and 
invasive behaviour (Ishiuchi et al., 2002). Therefore, here the mechanism of glioma 
cell migration on a FN/TN substratum in combination with migration promoting 
growth factors was examined. Whereas EGF, LPA and PDGF alone did not promote 
cell spreading and migration on FN/TN, combined signaling by LPA and PDGF 
triggered spreading and migration. Cell migration is an integrated process that 
requires coordinated regulation of various signaling molecules, including kinases and 
phospahatases (Laufenburger and Horwitz, 1996; Webb et al., 2002). Integrin-
dependent slow migration with a fibroblastoid cell shape is discriminated from 
amoeboid cell migration, where cells are round and do not depend on integrin 
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EGF activates Akt and ERK1/2, induces morphological changes, and increases cell 
motility in MCF-7 breast cancer cells (Garcia et al., 2006) and ovarian cancer cells 
(Oiu et al., 2006). This suggests an involvement of the Raf/MEK/ERK pathway in 
enhancing EGF-specific migration.  But, we observed that EGF did not promote cell 
migration in a tenascin-C context. This may be explained by an increased 
dephosphorylation and activation of the actin-severing molecule cofilin at  the leading 
edge by EGF, which lead to inhibition of lamellipodia formation (Song et al., 2006). 
Furthermore, EGF-induced activation of ERK5 can lead to the loss of actin stress 
fibers by a mechanism that is distinct from that associated with ERK1/2 (Barros and 
Marshall, 2005). Hic-5, a member of the paxillin family, showed tyrosine 
phosphorylation by EGF, which results in a decrease of lamellipodia formation in 
COS-7 cells (Avraamides et al., 2007). Thus, EGF prevents cell migration on a 2-
dimensional substratum via inhibiting lamellipodia formation through disruption of the 
actin cytoskeleton and focal adhesions. But, in 3-dimensional tissues, a round 
phenotype may support fast-track amoeboid migration. In this respect, maintained 
cell rounding on FN/TN by EGF could potentially be relevant in vivo and may 
promote amoeboid cell migration in tenascin-C enriched tissues. This possibility 
needs to be addressed in future experiments. 
 
In contrast to EGF-inhibited cell migration, LPA/PDGF triggered cell migration on a 
FN/TN substratum. LPA induces cell migration both through the G12/13-RhoA-ROCK 
pathway and the Gi-Ras-MEKK1 pathway. Rho is believed to act primarily at the rear 
of migrating cells where it promotes detachment (Ridley et al., 2003). In contrast to 
RhoA, Rac acts at the front to stimulate actin-mediated membrane protrusion. 
Activation of RhoA by LPA directly stimulates actin polymerization through activation 
of mDia, which induces addition of actin monomers to the barbed, fast-growing end 
of actin filaments. RhoA, mDia and ROCKs mediate phosphorylation of LIMK and 
subsequently inhibit cofilin. Polymerization through mDia and inhibition of filament 
turnover results in an increase of actin filament formation in response to RhoA 
activation. ROCKs induce actomyosin-based contractility, which is important for cell 
detachment at the rear. In addition, the concerted action of ROCK and mDia is 
essential for regulation of cell polarity and organization of microtubules (Wheeler and 
Ridley, 2004). LPA-induced autophosphorylation of FAK is required for LPA-
stimulated cell migration (Bian et al., 2006). FAK is involved in focal adhesion 
turnover, thus controlling the process of cell attachment and detachment, which is 
necessary for cell migration (Webb et al., 2004). In contrast to EGF, LPA recruits Hic- 
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5 to focal adhesions and to pseudopodia, suggesting that recruitment of Hic-5 might 
directly be linked to endothelial cell migration (Avraamides et al., 2007). Hic-5 may 
be an important molecule in LPA-stimulated migration through its binding to FAK 
(Fujita et al., 1998; Nishiya et al., 1999; Nishiya et al., 2002).  
 
Here, it was observed that only combined signaling by both growth factors LPA and 
PDGF triggered migration with a fibroblastoid cell shape. The underlying mechanism 
may involve an enhanced activation of MEK/ERK- and PI3K/Akt-associated 
signaling, which is triggered by either of the growth factors already alone. Many 
pathways are activated by PDGF that potentially promote cell migration on FN/TN. 
PDGF triggers rapid focal adhesion turnover, and continued adhesion assembly in 
concert with the spreading protrusion (Melton et al., 2007). LPA/PDGF-induced cell 
migration was PI3K and ROCK dependent, since inhibition of these kinases blocked 
LPA/PDGF-induced cell migration on FN/TN. PDGFR may be a target in 
glioblastoma therapy. Coexpression of PDGF and PDGFR has been shown at all 
brain tumor stages including low-grade astrocytomas, anaplastic astrocytomas, and 
glioblastoma multiforme (Maher et al., 2001; Westermark et al., 1995). The selective 
PDGFR antagonist CT52923 can block autocrine-mediated receptor 
autophosphorylation and the exaggerated Akt phosphorylation as well as the MAPK 
pathway, which was also consistently inhibited in some cell lines (Lokker et al., 
2002).  
 
By using cells with ectopic expression of syndesmos or reduced expression of TM1-
3, we showed that both, a strong as well as loose adhesion blocked LPA/PDGF-
induced cell migration on FN/TN. Syndesmos-overexpressing cells exhibited very 
little motility. Binding of paxillin or Hic-5 to syndesmos may lead to stabilized focal 
adhesions on FN/TN, which counteracts focal adhesion turnover during migration. 
Tubulin is another binding partner of paxillin (Denhez et al., 2002) and LPA induces 
formation of stable MTs (Cook et al., 1994; Nagasaki and Gundersen, 1996). MTs 
are essential for the polarization, the first step in the migration process as well as in 
promoting disassembly at the trailing edge. Thus, in cells with ectopic expression of 
syndesmos not only a stabile actin cytoskeleton but also stabilized mictrotubules 
might counteract cell migration. Another candidate is the syndecan-4 binding 
GTPase dynamin II, that colocalizes with syndecan-4 near the nucleus in the 
cytoplasm (Henley et al., 1998; Jones et al., 1998; Kreitzer et al., 2000). Upon 
treatment with LPA, dynamin II becomes associated with syndecan-4 at focal  
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adhesion sites. Thus, LPA/PDGF may promote dynamin II recruitment into focal 
adhesions and may counteract focal adhesion disassembly during migration.  
 
At the very front of the cell, in the lamellipodium, actin is nucleated and cross-linked 
into filaments and treadmill rapidly toward the cell body as the filaments elongate 
from their barbed ends. Filaments in this compartment are short-lived and 
depolymerize not far from the cell edge. Behind the lamellipodia is a more slowly 
moving actin network called the lamellum, which contains myosin II and 
tropomyosins (Gupton et al., 2005; Iwasa and Mullins, 2007). The results presented 
here, suggest that TM1 downregulation compromise actin treadmilling and through 
that cell migration on FN/TN. In contrast to the control cell lines, the shTM1 cell lines 
showed approximately 3-fold decrease in cell migration on the mixed substratum in 
the presence of LPA/PDGF, which indicates that TM1 is necessary for motility. The 
first step, actin polarization is supported by RhoA and RhoC (Wheeler and Ridley, 
2004), FAK and mDia (Wheeler and Ridley, 2004) and reorientation of the MTOC 
towards the leading edge (Jaffe and Hall, 2005). LPA induces formation of stable 
MTs and Rho-GTPase is necessary and sufficient for selective stabilization of MTs 
(Cook et al., 1994; Nagasaki and Gundersen, 1996). In TM1-overexpressing cells, 
cell migration is completely inhibited for all time points in the presence of LPA/PDGF. 
TM1 might protect actin filaments from the severing action of gelsolin (Ishikawa et al., 
1989) and from the depolymerising action of ADF/cofilin (Bernstein and Bamburg, 
1982; Ono and Ono, 2002; Bryce et al., 2003). Tropomyosins also inhibit the ability of 
the Arp2/3 complex from nucleating new branch points along the filaments 
(Blanchoin et al., 2001) and in addition regulate access to the actin filaments of other 
actin-binding proteins including tropomodulin (Almenar-Queralt et al., 1999) and 
myosin (Tang and Ostap, 2001). Through TM1-overexpression filament disassembly, 
necessary to move the cell body forward, may be decreased in T98G cells so that 
cells are not able to migrate on FN/TN.   
 
If actin filaments can be discriminated and targeted based on their TM composition 
then this becomes a powerful approach for anticancer therapy. Most importantly, the 
TMs found in the actin filaments of the contractile apparatus in cardiac and skeletal 
muscle are quite distinct from those found in the cytoskeleton of non-muscle cells 
(Stehn et al., 2006). It is therefore likely that targeting of a cytoskeletal TM would not 
impact on the contraction of heart and skeletal muscle, which identify TMs as an 
ideal candidate target in anti-cancer therapy. Both disruption and stabilization of TMs  
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could be desirable because both would interfere with cell migration. High levels of 
TM1 would also sensitize tumor cells towards anoikis.  
 
In summary, here it was shown that cell adhesion and migration on an anti-adhesive 
FN/TN substratum can be modulated by additional signaling from growth factors. We 
identified a minimal set of critical targets of tenascin-C downstream of syndecan-4 
that include FAK, paxillin, RhoA and TM1. Induction of EDNRA signaling by tenascin-
C provides an additional mechanism that contributes to maintained cell rounding on 
FN/TN by a mechanism that again affects the same set of tenascin-C targets as 
those downstream of syndecan-4. 
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